TRAIN2GAIN WHAT’S ON INSIDE SCIENCE CNIC & SOCIETY PULSE autumn’17 contents autumn’17 TRAIN2GAIN 4 INPhINIT, the training program that contributes to a good development of the professional career of the researcher during the PhD 6 CNIC coordinates a new EU Project to train a new generation of scientists for the future 8 ‘ACÉRCATE’: A+ science students train at the CNIC

WHAT’S ON 10 Valerie M. Weaver: “Most of the findings we have achieved have been through serendipity” 14 Marcelo Nobrega: “Bioinformatics will be key in the future” 18 Michael Sheetz: “Basic research has the possibility to go back and understand these biochemical mechanisms and find answers” 22 John A. Rogers: “We can carry a permanent diagnostic laboratory inside our body”

INSIDE SCIENCE 26 Excellence in scientific dissemination 34 Alliance for science 37 TTO or how to capitalize the investment of talent and resources of the academic centers

CNIC & SOCIETY 41 Their Royal Majesties the King and Queen visit the CNIC 43 Valentín Fuster, new president of the Health Advisory Board 44 A benefactor names the CNIC his universal heir 45 Second Anniversary of the Awareness Campaign “Women for the Heart” 46 Visit from the Health and Food Safety Commissioner of the European Commission 46 The Japanese Agency for Research and Medical Development at the CNIC 47 International Women and Girls in Science Day at the CNIC 48 March for science: ‘Move for the CNIC’ 49 The CNIC participates in ‘Scientific Weekend’ 50 Dr. Valentín Fuster teaches Master Course “Molecular, Clinical & Population Bases of Cardiovascular Disease and Health” 51 CNIC Awards and scholarships

COLLABORATORS: Editorial Committee Jorge Alegre-Cebollada Vicente Andrés Héctor Bueno * Borja Ibáñez Drafting Rafael Ibarra Content Editing Fátima Lois Layout and Printing Editorial MIC More about the CNIC at www.cnic.es For any suggestions or comments please write to [email protected] 3

autumn’17 PULSE

“As scientists we cannot live isolated from society”. This was said by Dr. Valerie M. EDITORIAL EDITORIAL Weaver, the Director of the Center for Bioengineering and Tissue Regeneration at the Department of Surgery of the University of California in San Francisco, during the VI Edition of the CNIC Conference. And this is the truth: our duty as researchers, and members of a global society, is to make sure that our knowledge, our results are transferred in a way that benefit the whole of society. CNIC Director Dr. Valentín Fuster Recently, the Secretary of State for Research, Carmen Vela, said that the transfer of knowledge between science and business continue investing in projects, hiring people, should be a circular concept. Us researchers and in short, mobilizing the country’s know that it is necessary to bring these economy. two sectors closer together, science and businesses. We must break those barriers And, during this time the TTO of the CNIC that still believe that companies need to be has accomplished remarkable achieve­ outside the university. ments, like the “Fuster Polypill”, the first polypill approved in Europe for secondary cardiovascular prevention which was developed by CNIC WITHOUT TRANSFER, researchers in collaboration with the pharmaceutical company Ferrer and that is approved for marketing in 55 THERE IS NO INNOVATION markets in Europe and America; the collaboration agreement between the CNIC and its technological partner There is no doubt that the transfer of Philips, which allows the CNIC to count with knowledge is the best way to give back the most advanced cardiovascular imaging the resources in research of the Public technology in the entire spectrum, from and Private Administration to the general ultrasound to hybrid equipment, through population. The main source of knowledge to CAT scans and Magnetic Resonance is the academic world. The question is how Imaging (MRI), and that has allowed for to capitalize the investment in talent and the development of the joint patent Philips- resources that is made in the academic CNIC VF-3DESSOS, ultra-fast MRI, or centers and to use those results for the the biomarker of the Pilar Martín Group, benefit of society. The answer is the OTRI. already patented for the diagnosis of acute myocarditis, and which is currently under Since 10 years ago the CNIC has had a negotiation for the joint development and * Technology Transfer Office (TTO), which licensing of the CNIC patent to a venture in this short period of time has managed capital company to develop a biosensor to transfer the knowledge and results of capable of detecting the biomarker in patient the laboratories and technical units of the blood samples in 30 minutes. center by providing an “added value” to the work, and in some cases, market products The conclusion is that without transfer, there that have an impact on the health care of is no innovation and without innovation, the general population. They also produce we are risking the future of research in our an economic return that allows us to country. ■ TRAIN2GAIN PULSE 4 e azu itnusmn ad n h Cro II Health III Carlos the in and distinguishment Maria Maeztu or de Ochoa Severo the with centers accredited the 3- a offered are who nationalities all of researchers young 57 selects to carry out a research of excellence. In every call, INPhINIT where environment competitive and attractive an offered turn in are who students, international outstanding hiring and encourage talent high-quality and scientificinnovative research in best Spain by the support Caixa’”, to ‘la aims INPHINIT Social “Obra Project Social the by Promoted health sciences andlife sciences. mathematics, physics, engineering, international technology, of fields young the in centers, research integrate Spanish best the in researchers to designed (Grant program program scholarship PhD a is INPhINIT the nº713673), Agreement ActionsCOFUND Sklodowska-Curie co- 2020-Marie Horizon Social and the through Commission European Caixa’” the ‘la by Social Promoted “Obra Project laboratories. center’s the any of in thesis doctoral their out carry to wish who chers resear­ predoctoral Program for center reception Predoctoral excellence, a as International of “INPhINIT” center the Ochoa” in “Severo participates a as CNIC, The the that

year work contract to carry out their PhD in PhD their out carry to contract work year professiona

contributes udd y the by funded l l

to career -

a

INP during the good in the internship that I did in the past in this group was group this in past the in did I experience that internship my the in because Also, understood. fully not still are disease the trigger that mechanisms pathological the nevertheless, and, year every world the around people of thousands affects it because attention my caught always has Atherosclerosis strokes. ischemic and attacks heart group, atherosclerosis, a chronic disease that causes most why “And field“ this in Jacob’sgroup?“ the of “Fortopic forthe reasons:first, two center leading a in PhD a do to wanted I sure for knew I and Netherlands the in Research Cardiovascularin degree Master’s the studied I good. very in research cardiovascular Spain. “Both the facilities and the technology and ease are in centers the important of one most is it opinion, her in because, program this in participate that centers other over CNIC the chose Rocío Atherosclerosis”, directed by of Pathology “Experimental group the joined already has welcomes CNIC the occasion, this On complementary training program. a given be also will They opportunities. mobility interdisciplinary and includes intersectoral, transnational, which plan development career professional a establish researchers the addition, In Institutes. Research

of

training

deve the

the h

researcher l

P Professor Jacob Fog Bentzon. INIT, opment

program h who Muñiz, Rocío D

of

opeetr tann porm o otiue o good to contribute to a program offers training it complementary “because adds, she addition, In CNIC. the as such excellence of centers research in student PhD a as Caixa three La a offered and the students international of program new at aimed a prestige, great a has itself is in which Foundation, it that fact the is apply to her motivated most which reasons the Among good option todothedoctorate.” recommendedprogramCNIC INPhINIT the the veryof a as With this intention, the scientific management department abroad. stay and studies my finished I once PhD the do to center the to returning of intention the scholarship with for possibilities look to me led CNIC which positive, the very at was experience “My CNIC. the at internship her impact. the of excellence quality, researchers, scope of the of benefits offered and the expected terms in training doctoral European revolutionize to aims INPhINIT programs. PhD their of one in interns INPhINIT the welcome which in Spain, centers research best the with collaborates INPhINIT excellent group leader.“ Finally, lot. a learned I and satisfactory very At thetimeofhiring,candidates mustmeetoneofthefollowing options: For more information: www.inphinitlacaixa.org • • • • • • • • • R The T o o e

learned about the INPhINIT program during program INPhINIT the about learned Rocío qu Additional training in transferable skills. transferable in training Additional 3.5 years. of period a in thesis the ofcompletion the of case the in PhD, the for 7,500€ of award An Very competitive salary. 3- higher). or (B2 English of level demonstrable a Have account. into taken be not will holidays as such stays Short hiring. of date the to prior years 3 in the months 12 than more for Spain in etc.) studies, (work, activity main their out carried nor lived have Not without careers research their of having obtained thePhDyet. time) full to equivalent research of (experience years four first the in Be out by theuniversity whentheadmissionprocess begins. carried be will mentioned previously studies of level equivalent an of verification The studies. PhD to access non- a in degree a Have Master’s the to correspond credits ECTS 60 least Degree. at which of credits, ECTS 300 grants which Educa Area) Higher tion European the of country another (or Spain in Degree University official an completed Have be

pr year contract. ireme

eli og g ram ible nts to to nts o , t , ffer he acce

ca s: n ss to I to ss dida Spanish university not part of the European Higher Education Area which allows which Area Education Higher European the of part not university Spanish t e N s s P m h - ust: I er contract year N I is an is Jacob T :

y rfsinl rfl a a eerhr lann from learning researcher, mistakes andachieving results.” a as profile professional my CNIC, the at as The Netherlands, Sweden, Denmark, etc.“ From her stay and such countries,European northern some in exist do which Spanish both trainingoutside the country due scientific to the scarcity of quality their programs, students, continue to decide many international, but Spain, excellent scientists, and in centers research good has that, “Spain limited. are believes options program scholarship PhD researcher the unfortunately, the However, of completion projects to organized inSpanishcenters.” the for on talent holding international by and national this to “contribute undoubtedly will INPhINIT,development.”as such initiatives, opinion, her In long achieve to way as a and involved, people the of values ethical and effort personal the to regards in especially view, of point a social from research of value the of recognition the instill to important is “It centers. Spanish in research promote to “necessary” absolutely are research, promote that kind, during the doctorate.” researcher the of career professional the of development hopes to “do a good PhD and develop and PhD good a “do to hopes Rocío Rocío believes that initiatives of this - em utial socio-economic sustainable term ■ ­

TRAIN2GAIN PULSE 5 TRAIN2GAIN PULSE 6 collaboration of the with (CNIC), Center Research Cardiovascular National the project coordinator. future”,the adds for scientists of generation new “a train to seeks that project this through carry and institutions “tremendously competitive” project to coordinate these 12 this for CNIC the in trust their placed has Union European the says scientists”, for young institutions of training European 12 involves that project collaboration training promote a “It’s industry. to and research academic between is European Program the H2020 of Union’s framework the within contemplated a duration of four years. The main objective of this project, and euros million 5 1, of budget a has (Switzerland), Bern coordinatedby Doctorate and Commission European Industrial the by financed project, This (EID) launched. was Microscopy” RegenerationAdvancedthroughOpticalDevelopmentand Heart of Analysis “4D project the 2017, 1st January Last CNIC C CNIC to

train Professor Miguel Professor Dr. oordinates Nadia Mercader from the University of

a for

new T from the CarlosIII fromthe orres A NEW A Professor

the

T generation The orres.

EU

future are partofthisnetwork. that universities prestigious the of one in industrial doctorate their the at training their partner’s facility. of At the end of this period, they will defend half spend will and supervisor sector industrial an and researcher an academic by supervised these jointly be of will Each researchers record.predoctoral academic their in excellence the account into took that process selection rigorous a after program the joined have who from Europe across researchers universities predoctoral 6 include will project The challenges ofthisnewproject. Prof. For worlds. separate in work often sectors academic and industrial however,the society; on impact positive a have to likely and uni­ obvious, seem between might industry exchange and versities open and free of benefits The T orres, turning this situation around is one of the key

of

scientists

PROJECT

the development ofthehearttoadultdisease.” embryothe of analysisof genes genetic stage the and link this at originate conditions heart adult Some important? real- in embryo an of heart the of development the the at look allows to it possibility since model useful a is but humans, away from further is which zebrafish, the is second the And, pregnancies). no or children unborn (studying embryology mammal and it is the best model we have where we can do a is it since model useful very a is which mouse, the first, the models: two studying are hearts We function. how and model develop and capture to techniques light different analysis applying image, the through heart the study of the on based is project “The treatment. potential to lead and disease heart could adult the of heart cause the discover embryonic the of regeneration and growth to According would beagreat stepforward”, says Dr. T lead to a new therapeutic approach for a regenerative cure There is no real solution, therefore any research that could best the in cannot cured, it be that is problem the And, years. 30 to 20 next the in cardiovascularproblem a have to expected are that people the all for treatment of costs the cover to able be not will countries that estimated is it and tremendous, is issues these with dealing of cost relevant.The veryfact in in are hours, work of loss the as well as suffering, social and especially problem, individual of terms health in failure heart of effects big The Europe. a is disease “Heart H 4D oehr eti caatrsis ht ae t pca: t is brings it special: project it make the that characteristics certain together 4DHeart, the of coordinator the For Tra ns P ns ear r t o jec Dr. Miguel Dr. t ie Ad h i te td i real- in study the is why And time. ae cnro i cn e stabilized. be can it scenario, -case T the real - the orres time image of the of image time orres. time • • • • • • • • • the with collaboration in place following academic centers: take will training The ifrn aaei rsac cres te rvt sector, patent protection private the careers, the research from academic choose different to able be will students program, the completing upon that, so extensive, and thorough very is project PhD Industrial this through provided training The period. training their of pro­ end the their at possibilities expand fessional will 4DHeart future research, their for postdoctoral participants the of training the Beyond field ofinnovation: the in leaders worldrecognized are 4DHeart in participate that of companies The part sphere. are international European that the companies four and universities four This project involves 12 institutions, four research centers, the companies.” academicinstitutionscollaborateuniversities thewith and the whichtranslational “inproject, bioinformatics.” a is itaddition, in And, and physics together biology, joining subjects: different implies which and regeneration, heart its the during of development the during behave cells how technologies, imaging new the using detail, great in different country”; it is transdisciplinary, “it’s about analyzing transnational,“that is,students have theirdoto thesis a in

Microscopic Image. Interactive in companies leading the of one Bitplane, Royal of Divisions Philips Electronics. Product the of one Iberia, Philips and measurement analysis ofmicrostructures. visualization, scientific the the for of experience needs image technical advancedinnovationand throughcommunity the supports that Company a Division, Science Life Microsystems’ Leica for required tools screening applications oforganisms andcells. and instruments experiments, of Acquifer, that integrates experience for the development diinly te wl cut n h tann given Strategies. training participants. the also on by count are will Empresa they Additionally, de Instituto and Starsbourg, of University (UC3M), Madrid of III University Carlos (UAM), Madrid of University Autónoma The Michael Liebling. by led Bioimage, Computational of group the Idiap multidisciplinary Research Institute (IDIAP), with the basic participation of of centers research inEurope main the of one of Genetics and Molecular and Cellular Biology (IGBMC), The Supatto. by coordinated projects scientific and which counts on an interdisciplinary group of researchers (France),Palaiseau ResearchCenterin (CNRS)Scientific National the of Laboratory Biosciences and Optics The Mercader. scientific and be will social representative Its importance. great with research of areas in institution leading a (UBERN), Bern of University The Juan Professor Julien Vermot Laboratory at the Institute epr o Sine Communication Science on expert Sarasua, ■ . Professor Professor Willy Professor Professor Nadia

TRAIN2GAIN PULSE 7 TRAIN2GAIN PULSE 8 Pilar Frías María Ana se Adel Aster students, young eight the occasion, this On women. 59 and men areprogram, 37 the in participated alreadyhave students 96 total in year, this of those Including Madrid. from student another and Community, Mancha Castilla-La Valencian from one the from three Andalusia, from students three selecting year this off country,finished the throughout students school high senior to open call, The research.” cardiovascular of field the in researchers excellent of pool a create to ages earliest the from people young brightest the center, of Director General the of goal personal a plan, this CNIC its within (CNIC) Center Research Cardiovascular National III Carlos the 2 by organized last program, ‘Acércate’ the the for scholarship in a average of recipients lucky 10 the been of have school, high out of years 10 a with Spain, in students school high senior best the of eight again, Once A+ oehr with together is theonethat is aimedatattracting theyoungest talent. this CNIC the at available programs training the all From visits. recreational and cultural includes that program leisure a complete they addition, In life. university their be to sure is what anticipating ‘Acércate’ days, 15 for Hall Residence a in stay the experiments, youngsters the Therefore, too. side advanced a playful has program most the technology and latest the with touch in being to addition In must make apresentation totheirresearch supervisors. they program, the of day last the on Also, activities. other comparative among bioinformatics, activities, or genomics proteomics, medicine, transgenesis as such research, students CNIC, perform various activities that help them get in touch the with at are they that days 15 the During the “future ofresearch inourcountry.” are people young because researchers future attracting in key is stages educational early such in program training CNIC. the of Director with doubts also and and researchers, center’s experiences the their with share to CNIC, able the as were such they research in excellence of center a of day’ to ‘day the in participating besides Campillo, Portero and Marchante González r Vlní Fuster Valentín Dr. ml Eskandarous , Gamil - and Carrera Albaladejo Raúl Young Training Plan. The objective of of objective The Plan. Training Young science Serrano, believes that starting the starting that believes Fuster Dr. , is “to attract and train the the train and attract “to is , Carmen at Hernández Marta rn Cnvs Cervera, Cánovas Irene rí Fernández, García train ‘A r Fuster, Dr.

students Gabriel Solís, cércate

at myself toit.” dedicate to likewould I future the in if decide therefore,to and, is really research what of vision “a have to her help Cádiz student The experience.” gain to was and knowledge Program my “The it: about expand to opportunity,both unique a twice as me to introduced think not did she program, the know to got she as soon as that recognizes “incredible”. as program the rated students The years ago”, addsDr. Fuster. “We are very satisfied with this concept that stage. we started 12 earliest the from be talent capture to to continue and celebrated can it year, after year that, so essential the of support sustained The R eal R

e the s a cer ht h Porm could Program the that clear was Frías Ana earch

CNIC is Foundation CNIC Pro Carmen ’: -born Northern Europe and American of level the at – quality high and leading a the different departments that make the existence of such working there, but also because of the coordination among not only because of its size, resources and number of staff me, to center incredible an like seems CNIC The Spain. in wonder unique a is Program Acércate “the that believes And experience. incredible an this make are to included activities recreational and cultural that appreciates while well research, very translational for a center inside prepared get to her allowed has it as riching”, For te xeine a be “rmnosy en­ “tremendously been has experience the Marta, - research center possible.” ‘Acércate’ students in 2017 in students ‘Acércate’ ■ Gabriel Raúl ht hs ciiy il norg mn scientific many encourage vocations. will activity this that hopes and students school high senior and junior to work its shows CNIC the center, the of staff the of offered by Science Week. Thanks to the collaboration research may start earlier and this is the opportunity center.the at weeks two spend However, interestin year final high school students brilliant from around the eight country to invites Program ‘Acércate’ The talent to the most advanced cardiovascular research. attractyoung to is CNIC the of objectives the of One career really involves. research the what or researcher a become to how learn to able were VallmontSchool, the and School, Camino del María Santa School, Zurbarán School, Castilla from Nueva Villafranca, Zola School Bilingual students the school high senior and junior 200 around which in CNIC, the at held was Conference’ Research CNIC to Close) (Get ‘Acércate the young, the scienceto objective“bringing closer” the of With ‘A R e c s é earch rca Julia Redondo, Rebeca Acín, Guadalupe Sabio, Sabio, Guadalupe Acín, Rebeca Redondo, Julia Leticia Herrera and María del Valle Montalvo Valle del María and Herrera Leticia t e ( Con Ge t t C fere l os n e ) ) to C ce ’ N IC IC

TRAIN2GAIN PULSE 9 WHAT’S ON PULSE 10 eatet te AR acetc cin ewr Aad ad h Wmn n el Biology Cell in Women the Defense and the Award,Mid­­ from Network Award Action Expansion Pancreatic Scholar AACR the A Department; and Award Scholar Cancer Breast awards: different with recognized been have accomplishments Hercancer. of development the in and focuses on the contribution of cell-intrinsic matrix as well as extracellular forces in oncogenesis leading the interdisciplinary research in Oncology for more than 20 years. Her current research at the Surgical Department of the University of California in San Francisco. Dr. Weaver has been Regeneration Tissue and Bioengineering of Center the of Director the is Weaver Dr.M. Valerie Valerie M. Weaver human disease, development, etc. of field the in experts mechanobiology, international from different together areas gatheredof experience: that technology, cellular event biology, animal scientific models, a disease”, and participated in the Sixth Edition of the CNIC Conference, entitled “Mechanical forces in physiology UNIVERSITY OF CA OF UNIVERSITY Career Award, in acknowledgement of excellence in her scientific career. The researcher The career. scientific her in excellence of acknowledgement in Award, Career “M have serendipi ost we L

IFORNIA, SAN FRANCISCO (USA) FRANCISCO SAN IFORNIA, of

been have

the

through

achieved findings TY ”

WHAT’S ON PULSE 11 WHAT’S ON PULSE 12 two fields of investigation. The first one is centeredtheinvestigation. isonfieldsof one twofirst The intocellularbehavior.investigationdivided Ourprogramis the alter tomatrix’sorder receptors,thein functionof the compositionrelatedareitswithorganization, and regulate the that matrix, how the of properties investigating topological and mechanical are We destination. cellular modulatethe receptors matrix extracellular these which by Specifically, homeostasis. my and group development is tissueexploring the the molecular regulate mechanisms cells stromal of interaction the how determining on microenvironment.theirwith have Concretely, working I’m mothercellsrelationsthethethat into look to likewould I What “truth” are you lookingfor atthismoment? be. to world the want they how about reflect to able are they that is idea The groups. cultural and economic social, ethnic, and subjects different from researchers of team a up make I the when be do to try I should what is that we truth”. And, the of “seekers supposedly, And, is. truth knowing the is key what The it. find we when truth the admit to enough humble be and way a in different work our see us help that ideas others’ from learn people, other to listen things, see to us enables modest Being there. already is what from rather, learning but things, discovering not are we in reality, Because, humbleness. be a researcher: good to requirement another is there are, you intelligent how and have you training much how matter is No it enough. not but be, to have you researcher a be to order in and intelligent, are daily, classes my in this of lot a see I and scientists, Most be creative. must they career. In addition, scientific good a making in have they possibilities more the questions, answering in most have they interest the more the curiosity: is opinion, have should my researcher a in In quality important helps qualities. other mentor should many researcher a a have but having career, that scientific a doubt, developing no is There have? In your opinion, what personal qualities should a researcher order tobeabledevelop theirscientific careers. in need they what have they that so people young other sponsoring myselfto work my of part large a dedicatedhave and of most the give to tried have I be. to want they what be and study to want they what choose freely women can most nowadays and lot a changed have young things a Fortunately, what time. that at life wasn’t her with do should that woman because shock, in almost surprised, very was mother my and traditional very was family my that was problem The young. very was I since it knew I And, nature. my in was research reason, some the though as Forcareer. scientific was a develop to was It do to thing natural. natural very was it case, my In Since when have you beeninterested inscience? involved inthispassionatecareer thatisresearch. thereand ideas, are more moreand young get that people original very to ourselves lead that ask questions interesting we most reach; the our at tools endless have We At this moment developing a scientific career is a privilege. For you, what doesitmeantobeascientist? - epithelial That’s why I work from the most basic till the clinical. clinical. the till basic most the from work I patient. why the That’s until nano, the – smallest the from research covers of idea My direction. that in work way, that in and nano, the to back going to are things important most we what the clinic, can researchers with the define clinical the to basic most the from travelling way, This clinic. the to the from reaching and capacity tissues, of research the through going nano, approaches, the different is combine research and people of integrate can line I intelligent this that believe to many I contribute what are but field, this there in researching that aware I’m think you can contribute toit? you do What particular? in field this choose you did Why mother cells. adult embryonicand the destinationof the on has matrix extracellularthe of strength the that role the out figuring on focuses second, the and development, tumor the and tissuebreast the developmentof theinfluence matrix the understandinghowofthecomposition andorganization of n Fr xml, eety e icvrd oehn that something discovered we recently example, For on. working really not were you that something in a discovery make you times of lot a that is reality The all. it know we that believe cannot we important, is modesty think I why is that And serendipity. through been have achieved collaborate with one to another. Most need of the groupsfindings we have the All people. of groups other with also and research, my from benefit really could that patients with example, for relationships, of lots have to try I case my In society. from isolated live cannot we scientists, As to transmitted be society? advances scientific the should How etc. perspectives, areas, ideas, different of conciliator” or “integrator an as myself see I ways, some In team. great a such or collaborators great such have didn’t I if research of type this do to able be wouldn’t I highlight: to like I’d that something there’s And, truth. the find can we line, this of point one at that believe I me. for enough not is area one in just in Working Schwartz, from Yale Martin University (US by and (CNIC) Pozo del Á. Miguel and Montoya Invited by Jorge Alegre-Cebollada, disease’, 4thand5thofNovember 2016. and physiology in forces ‘Mechanical Conference: CNIC talk aboutscience. example, for me it’s a privilege that I was invited to CNIC to a privileged group and we have to be conscious of this. For the image that we give is very negative. Us researchers are with If we are arrogant and we distance ourselves from society, debt doing. are in we what transmit are to is obligation we Our society. that forget marvelous. cannot that’s And, we basic. However, most the to back, go me makes that happens something doing, I’m what know I to predict that I’d have these results. Every time that I think able been have I would years million a in Not researchers. clinical the with chemoprevention on trial clinical doing pilot are a we now and before on worked never had we in makingagoodscientificcareer.” the more possibilitiesthey have in answeringquestions, the more interest they have a researcher shouldhave iscuriosity: “The mostimportantquality ■ Nadia Mercader, María A).

WHAT’S ON PULSE 13 WHAT’S ON PULSE 14 is getting better each day; for example, thanks to the the to thanks example, for day; each technology better because getting favour is our in plays time In one. addition, each of mutations specific the allow investigate with to will us this patients that profiles, of genetic is and groups idea variations different different The compare genetics. can of we field if the focus on to mechanisms career decided I my why different That’s pathologies. in about involved in is information genetics powerful obtaining how realized I a as and train to researcher started I medicine, in mechanisms degree my After the finishing diseases. trigger by and underlie fascinated that processes been and always have I What exactly isyour fieldofresearch? and variation genetic “Regulatory human diseases”, entitled invited by MiguelManzanares. CNIC the at seminar a gave Nobrega Dr. disease. heart congenital and developmentcardiac control that genes of regulation the on focuses also in published was study His composition. body and mass body the regulates which Irx3, gene, obesity real the be to appears what identified team Nobrega’sDr. diabetes. the or obesity like diseases, of human many of cause the be malfunction might genes the of programs regulatory the that believed is it because Nobrega, crucial, For is networks. processes regulatory these their understanding in genes of function and architecture the on (USA) Chicago of University the at Genetics Human of Laboratory his at works Nobrega Marcelo Dr. Marcelo Nobrega UNIVERSITY OF CHICAGO (USA) CHICAGO OF UNIVERSITY “B ioinformatics in

the wi specific mechanisms of certain diseases. diseases. certain of mechanisms specific the with genes, the outside identified already mutations, these relate to technologies of design the on I work work. my heart develop I a where is to This etc. diabetes, susceptible cancer, attack, more us make that mutations these precisely is it And genome. the of in area” “grey occurs this what about alterations; little suffer very know we doesn’t reality, it in but stable, is genome the of 99% the them. of outside but that genes the in not are know mutations we now And pathology. cardiovascular the like diseases, several in involved genes mutations the the and on information obtain and individuals of many genome the analyse can we Project Genome Human

futur ll ll be

key His work His Nature. E”

WHAT’S ON PULSE 15 WHAT’S ON PULSE 16 tre tkn m t sho we I a js to years two just was I when school to me taking started she because fault, mother’s was my was I It old. when years 15 just it studying began I as student, precocious very a was I fact, In Brazil. in degree medical my studied I What madeyou orient your professional life to research? no circumstances could thesebeswitches. under But therapies. future for targets become could that mechanisms the on information get will we genes these of functions the studying by And predisposition. such in cardiovascular to involvedare that genes the find definitely predisposition will we disease, greater a favour that Not really, no. However, when we study the genetic causes gical targets? pharmacolo­ into converted be then switches these Could obesity the gene iswhatoccurs inmany other diseases. with happened that same the that is know we what And, one. “bad” a into gene good a convert and activate that ones the the mechanisms certain is of it mutations that understand to difficult It’s switch. the but obesity, causes that gene the not is it reality in No, gene. obesity the was thoughteveryone which gene a activated that gene a inside switch a is time that at found we What example thatwas publishedontheobesitygene? the in like diseases, of origin the of cause the this is And consequences. pathological has this And repressed. nor activated neither is gene correctly,target thereforeDNA the and the to bind not do factorstranscription the mutation, a is there when that believe We sites. binding factor transcription these modify or alter to capacity the have mutations these is that believe we what And genes. deactivate or activate to proteins other recruit to capacity the have that binding proteins DNA are they sites; called binding is factor what transcription of clusters basically are switches These are mutations these why activated? or how when, know you Do that ishow diseasesare provoked. and lost, is balance this switches genes deactivate or activate these that in mutations are there when that We think not. others and gene, certain a activate to them for order in cells the to transmitted is information this where genome non-coding the of part the in precisely is it And developidentity.to their genome differentthe the of parts use to how know cells these Somehow, fascinating. is It heart. the with occurs same the And instructions? same the and code genetic same the have cells our of all if gene this activate to how know pancreas the in ones the only do Why it. do pancreas the of cells the of some only but insulin, produce to information genetic the has organism our of cell each example, For genes. the of expression the regulate to importance its in lies question that to answer the of part that possible is It do? genome the of rest the does what So proteins. produce letters these of 30,000 the genome. The genome has three million letters, but only of 1% merely involves the proteins the of codifies that part genome The mutations. non-coding called are They What typeofmutationsare they? There are more and more professional experts in bioinfor­in experts professional more and more are There complex mechanisms in order these to redefine our ideas and hypothesis. on focus complex. to going more is research and our so more And be will which ourselves, we ask that questions the polish to able be to going are them, we to thanks precisely And a way. in sophisticated but more years 10 last the in developed technologies been same have that the using continue to going are We today willbecompletely different?it know we as science years 10 in that mean that Does a fundamental science work willsurely fail. my to do who laboratory. The programs that do experts not approach “coding” as those attract to money enough get to need I why is In myself,which it master field. not do I this fact, master not do you if future the in scientist now.competitiveYou almost a already be is cannot it and or future, transition,the keyin be will revolution.Bioinformatics almost of time a in are we fact, In genomics. and years ago was a chimera, especially in the field of genetics in. Right now we have tools and knowledge that just a few privilege to research at this moment that we find ourselves a it’s financing, economic the aside put we If right. That’s fascinating, right? Youforresearch,also complicatedtime but a is it that say should decideexactly whatyou want todo. you doctorate the of years last the in that is recommend I that Something industry. the in work reporter, scientific assistant, science: in options other are laboratory,there a run to going are scientists all not corners; many are there thing that I always insist on is that in the scientific careers give answers. And if you fail, start over again. And another to try and day every questions yourself ask and Ask day. to day your in ambitious very be and capacity your all of 100% give to have You hard. really work to have you so into account: we are talking about a very competitive field, up”. Then there are many other aspects that must be taken give “don’t is advice principal my reason, that For slowly. you want to work in this field because things advance very financing, consequently, now you have to be very patient if has research in situation changed a current lot. In some the cases, for the worse, that if we talk is about truth The young a that quality one researcher shouldhave? the opinion, your in is, What working there. researchers 9 my of total have a with I Chicago, ago in laboratory years own 11 Since ago. years 22 was that And USA. the in program research a for applied I degree, I what loved medical my I finished I when and laboratories these in USA. saw the in stays temporary in on, and later Brazil, in university a my in at first work laboratory, to research opportunity the got I Fortunately, wrong. go could it why and involved mechanisms the produced, were things how knowing was liked I What boring. was it clinic: the to got we when started is problem The basic. very everything because pleased, very was I degree my of biology,physiology… yearstwo first That’sthe during why liked I dream. my not was it medicine, study to want not did I reality in But, advanced. so was I why that’s and old, h sinii fed s ul f alrs Te a t dy is day to day The failures. of full is field scientific The ting moment inyour career? Do you remember any particularly important or disappoin­ for my students it writing scientific articles, reading and acting as a mentor of most spend actually I researching, time the of rest the spend I that mean doesn’t that But, week. a hours 10 to 5 than more not is it case, my In work. administrative to hours some devote to have still I community, a of part as is “protected”, so I can dedicate a lot of time to my lab. But oriented my career in a way that the most part of my time have I but well, run to laboratory my for order of in part job my necessary a it’s know I tasks. try these I delegate to so organization, to comes it not when am disciplined I very work. administrative hate I that admit must I What isanormaldaylike inyour laboratory? in thenext10years. Further thanthat,itishard tosay. Atleast knowledge… innovativedevelop of areas will who ones the jobs, interesting most the find will who ones the be will they areas: two these combine that those be will researchers good the future, the However,laboratories.in our of part them make and analysis data in professionals those hiring by laboratory my in “gap” that in fill to try I to required training the analyse have those data bases in the right way. As I said before, not do we experienced, very are myself, like researchers, while analysis, matics from the possibility of solving problems of nature that nobody has succeeded in doing so until now” exist” not does moment, “Eureka” the of idea romantic “The Invited by Miguel Manzanares. ses”. Seminar “Regulatory genetic variation and human disea­ eesr t d eeyhn aoe ad ot certainly, most and Miguel’s group isonewithwhomwe willcollaborate. alone, everything do knowledge to or necessary experience the has Nobody laboratories. we our between collaboration formal a won establish to going are no from and before times many Manzanares, to wanted host my with collaborated informally always have I come. have I but CNIC, at been never had I What isyour opinionofCNIC? must beconstant. makedifficult to be will it researching yourcareer. Passion capacity, that have not do you if And, now. until so doing in succeeded has nobody that nature of problems solving of possibility the from comes satisfaction intellectual The job. special a such with pleased be should people think I And together. come to research of pieces the all for step, by step possible, it make that satisfaction intellectual of moments little are there But before. it experienced never romantic I’ve The least at exist, not does progressing. moment, “Eureka” the of idea continue little, by little and problems, solve and forward go to way only the It’s way. to be obsessed with what you’re doing, but it has to be that Youfrustrating.have sometimes and boring monotonous, “The intellectual satisfaction comes satisfaction intellectual “The • Miguel ■

WHAT’S ON PULSE 17 WHAT’S ON PULSE 18 Michael Sheetz CO MECHANOBIO and by MartinSchwartz, from theUniversity ofYale (USA). Pozo del Á. Miguel and Montoya María Mercader, Nadia Alegre-Cebollada, Jorge researchers CNIC the by organized event disease”,scientific and a physiology in forces “Mechanical called conference CNIC the of edition VI the in participated Sheetz Professor illnesses. other among cancer, and problems heart both for drugs of discovery the permitted forces2012, in Award molecular Lasker which by steps the the awarded was he revealed which fordiscoveries, His work. mechanical into energy chemical and convert protein motor kinesin the of the to discovery led achievements His motors. molecular of study the in promoters biggest the of one been has and years 40 than more for field biomedical the in working been has Sheetz Michael USA. the in University Columbia at professor and Singapore of Institute Mechanobiology the Mechanobiology,of field the in of directorpioneers the the is of one ProfessorSheetz, Michael these and L UMBIA UNIVERSITY (USA) UNIVERSITY UMBIA

UNDERSTAND

biochemica and L OGY INSTITUTE (SINGAPORE) INSTITUTE OGY

FIND has to

GO BACK GO asic “B

the l l mechanisms

possibi

answers research l ity ”

WHAT’S ON PULSE 19 WHAT’S ON PULSE 20 Are these factors involved inall thediseases? produced. are forces physical because elements these how understand to unable been mechanical have we now until and biophysical these by Now we biochemistry. are to go about trying into detail dominated were biologists the because overlooked been had process whole this past, the In physicists. biological and biochemists bioengineers, with collaboration in work and why to need we that determine for And produced. to are events these is how challenge big Our same. the way, almost result final the makes same that And independently. but the in essentially twins two the on are working factors biomechanical these all and forces these all twins, in example, For quantity. right the in and way right the in cells associate to them inside information the our have and following: the matrix, extracellular the with and cells other is with interact cellular context the The influence environment. that forces access depth these in can on get and knowledge we investigate bioengineers, to tools of useful extremely help the to Thanks of type this center your research inthisfield? use to people first you did Whyresearch. biological in techniques mechanical the of one were You can they beresearchers” and asktherightquestions “Only ifthey are curious processes thatprovoke itsdeath” role inthecell’s biology, including “Mechanical forces play animportant of knowledge from the bits, of the blocks of information information of blocks the of bits, the from knowledge of structure a construct gradually to is have We this way. and long a forces; mechanical the of integration the in involved are that structures the all of knowledge global more a have we until forward go can we that think don’t I more. out find and questions more myself ask to want I know moment. this at in already interested I’m we what not it’s what but now know only I Actually, exciting. very is field this in answers finding and questions Asking I’m months. six next the in doing be I’ll because what sure is entirely not it, enjoy really I in that research, fact the of to field addition this in continue I why reasons offers the politicians. that research with finance to problems short willing many only are so They have we short why about talk to risky seems It What can we expectinthefuture ofthisfieldresearch? its death. provoke that processes the including biology, cell’s the in role important an play forces Mechanical others. among are involved in the development of cardiovascular disease, forces mechanical these that seen have we little by little but certain, are we which in first the is YesCancer indeed. - term results, one year, for example. But one of of one But example. for year, one results, term - term results. That’s That’s results. term happens sometimes when you are conducting an an conducting are you when sometimes we This way. that right happens the in understand researching to or working relevant not were very point was it personal a view from of labo­ frequently, our quite which makes discovery, ratory important an than Rather moment inyour career? Do you remember any important or especially discouraging is goingoninindividuals. what determine to matrix, cell its the with and surroundings with relates cell the how example, for like, analyzed already issues same the investigate and questions same the ask and back go to necessary it makesnow. This until classical the understanding biochemical model, which biophysics had in not incorporated elements critical were promotors physical the that me to clear became it detail, activity and when I started to investigate this field in biologicalmore on influence their and controls physical the in interested become to started I physics. biochemical and biochemistry of field the workedin have I years,Formany When didyou decide toresearch inthisfield? this in advance to knowledge. able be to order in out, find we that Schwartz, University ofYale (US ría Montoya and Miguel Á. del Pozo (C NIC) and by Martin Alegre-Cebollada, Jorge by Invited disease’. 4thand5thofNovember 2016. and physiology in forces ‘Mechanical Conference: CNIC basic mechanisms, in order to advance in the design of of treatments. design the in advance to order in mechanisms, basic most the understand to step, first the is It answers. find very and mechanisms biochemical these understand and back are go these to possibility the has drugs, research basic However, fragile. some with the analyze rationally you If research either. patient the for benefit real a generate don’t they cases some in that fact the despite with work they why harm, any provoke to no is proved been have that methods That harm. of to type not any principle: cause basic one have clinicians and Doctors account. into taken be must aspect one However, Right. and basicresearchers? researchers clinical between occurs what to similar it Is way. It’s achallenge. another in them at look and them reconsider to have theymay that possible is it and assumed, already were that issues some to back go researchers the makes it because biochemists, etc. And this interrelationship is very valuable findings to their biologists, and the same is true with physicists,explain to physicists for is it difficult how know all We languages. scientific different their in seeing, are they what doing, are they what share and other each amongst speak can they together,so are laboratories the therefore same the type, any of separation or walls no in are there where space together, work to biologists and physicists,chemists for is Singapore in center our at do to try we it”. It’s certainly not, the best way to act as a mentor. What about me tell and learned have you what with years two in “comeback them: told and them at fish a threw he day One German attention. his demanded old students the whom teacher an about anecdote an you tell to going I’m How important isthefigure ofamentor inresearch? the right questionscan they begoodresearchers. ask and curious are they if Only possible. way precise and how certain events occur and develop in the most detailed this career must be marked by their desire to truly discover follow to and researcher a be to decision Their Curiosity. young a that quality one researcher shouldhave? the opinion, your in is, What that iscorrect. information new obtain to way right the signaling is that itself nature is it rather but mistakes,exactly not are They Is itaboutlearningfrom your mistakes? place. first the in you predicted had what not are results the why understand truly you that is circumstances these in doing precisely it’s And are correct. not you what that confirm to someone find to have you when occasion that on It’s first. at thought had you what from different are results the and experiment ■ A). adia Mercader, Ma - Mercader, Nadia

WHAT’S ON PULSE 21 WHAT’S ON PULSE 22 John A.Rogers UNIVERSITY OF OF UNIVERSITY i ll inois (USA) in tears, willbeusedinthe future todiagnoseanumberofdiseases. like fluids other use also can which systems, these that trusts Rogers risk. at is health our case in take should we that measures the of us warn and phone mobile our to analysis the of results the send can that and back the on or arm the on put be can that device single-use verycheap, A health. of state our check to essential are that sweat biomarkersfourin found time real in analyze to capacity the has and thickness, and size in small very is which patch, magazine the in study a published has group Rogers’ of thedigitalera. of form revolutionnext the developmentbe could technical that a biosensors, the and electronics portable in materials, micro/nano of types tapes, wires, membranes, tubes or the like. Some of his contributions are related unusual to the field of other with these of combinations hybrid as well as tissues, biological and crystals liquid polymers, like materials, “soft” of tics characteris interesting exploit and understand to tries group His health. on bioengineering of Dr. John A. Rogers, from the University of Illinois (USA) has spent years applying his knowledge

our “W a

l e permanent

aboratory diagnostic organism

can

carry ”

on a skin Translationala Science on Medicine -

WHAT’S ON PULSE 23 WHAT’S ON PULSE 24 our body? into incorporated doctor a have all we will future, the In that are released attheright timeandplace. drugs integrate and research microfluidic with together optical stimulation,etc.Andinthefuture we hopetowork perform to order in systems optogenetic with combined be also a can they like but rate, pacemakers, of heart type sophisticated the control would that stimuli small the example, For generatecould heart the or brain the integrated application.in devices therapeutic a have also devices these diagnosis, on focusing is work our Although Do they alsohave therapeutic applications? start to hope we testing onhumansnextyear. and models, animal on worked only in the brain or the heart, although at the moment we have those that can be integrated inside the organism, especially extensive. very is devices, internal the on work skin to continueFurthermore, we the on devices “external” applications the of of number The etc. temperature, body the pulse, the devices blood, the Other in oxygen time. of level over the evaluate way can continuous a in measurement done the is since electro, an than fidelity clinical greater a electrocardiogram,with an for need the without heartbeats the measure will they chest, the on placed are can that usually only be done in hospitals. Thus, if for example they parameters physiological of series a measure the on can they located, depending are they where body our of area specific and, skin our to adapt they unique because are platforms of type This health. our to related parameters physiological certain about information with us provide that and now right on have I one the like skin, the on put are that devices the to referring I’m people. on prototypesour on trying and Wewith workingalready are on aroutine basis? clinic the in use to readydevices these are opinion, your In and clinical, asadiagnostictool. discoveriesbiologicalresearch,make new uses: to defined platforms technological have a diagnostic application. Actually, they have two very these researching, to in addition But research. neuroscience in depth in more go to us allowwill tools examplenew one howthese just of is This neuroscience. some in get questions to fundamental the start to will answers we devices these through it knowledge on in-depth more get can we if why That’s etc. develop, diseases some how works, it how know not do we times Many organ. sophisticated very a is brain The What would theapplications oftheseplatforms be? for the pancreas, kidneys, etc. This is just the first step. heart, brain and skin. Our intention is to generate platforms notonlyusethemexternally. We don’t wantstopthetoat way,wecanintegrate thedevices inside theorganism and forexample, batterieswhich arecompatiblethisin that so develop, to trying are We applications. more many willhave they think we But skin. the and brain the heart, the on platforms these with working are we moment the At bio-integrated electronic systems in the field of cardiology? these investigationof the on situation current the is What information inreal time. high-quality and precise more with them provide to not if professionals, medical of work the on take to not is idea controls the main physiological which health parameters. But the bodies our on diagnosis of a laboratory carry permanent can we devices these With that. like Something only bedoneinhospitals” parameters thatcanusually they canmeasure aseriesofphysiological of ourbodywhere they are located, and, dependingonthespecificarea because they adapttoourskin “These typeofplatforms are unique Invited by Jorge Alegre. Cardiovascular Research”. Electronic Bio-integrated “Soft, Seminar ways towork together. have had during my stay in Madrid, we will most likely find we meetings the of some incredible after that has believe and I also experience. field; facilities, its cardiovascular from apart the center, this in common in research of areas many have We future. the in CNIC like center a with collaborate to interesting very be would it course, Of ration have you seen? collabo­ for possibilities What CNIC. to visit first your is It many ofusare doing. that thing same the do to mentors future the educate to it’s not just researching, but rather that mentoring is a my way of some believe I howcareer. scientific important very a have see students to satisfaction great me gives it and pleasurereal with it do currentlyperform.I I that task It is possible that at this moment this is the most important How important isamentor inascientific career? key. are these me, For mindset. interdisciplinary an with good and collaborators, generous, of summary, lot In a fields. have other in that experience collaborate areas to other how from know researchers with should They view. of point to have they a multidisciplinary from that career their contemplating realized begin have I years last the in But them in of the importance really understand good getting training. instill them make to to try and try generous, being like I values, some laboratory. my in young researchers many with worked have I years, the Throughout in scientific research? What advice canyou givewho begintheircareerpeople to the students, whoare very enthusiastic inthisfield. to thanks also career,and exciting this in ourselves found have we biologists and clinicians to thanks But, health. to interest any of be would it thought actually never had we although neuroscientists, the to interest of be could work our of all discoveredthat Wedevices. electronic flexible of design the haveworkingon I been frombeginning and the years, for engineering materials of field the in been have I your research? of applications health the on focus to decide you did Why revolutionary ideasare greatly neededinthisfield. charged inside our be own body through movement. can New and example, for that, batteries obtain reduced, to be related mainly must but size their is say, to is sophisticated, That batteries. to more increasingly becomes bioelectronics as future, the in with faced be will we that challenges the of another Furthermore, health. in use for regulatory health the authorities that bywill allow their production on a approvallarger scale subsequent its and these of all practice clinical in that safety the is pose challenge devices bioelectronic biggest the opinion, my In What isthebiggestchallengethatthesedevices pose? ■ S ses for ystems

WHAT’S ON PULSE 25 INSIDE SCIENCE PULSE 26 nuym i Mra snrm ad eae diseases. related and syndrome Marfan in aneurysms of an enzyme prevents and reverses the formation of aortic injury after a heart attack, and the discovery that inhibition mechanism decades the a which through lymphomas, the for aggressive target of new treatment a overturned, dogma’ ‘scientific A communication promoting lysosomal degradation of MVB proteins. MVB of degradation lysosomal promoting doi:10.1038/ncomms13588 Madrid, F. (2016). Sánchez ... O., Moreno -Gonzalo, D., Torralba, I., Delgado, Villarroya-Beltri, C., Baixauli, F., Mittelbrunn, M., Fernández , Communications Ex 7,13588. ISGylation controls exosome secretion by by secretion exosome controls ISGylation L l du ses h sra of spread the stems drug -old eading ce j o ll u

ature ature N rnals - - science , , Communications , , Blood A team of CNIC scientists led by led scientists CNIC of team A in intercellular communication CNIC scientistsdiscover akey signal . JACC munication between cells.” com­ therefore and exosomes, of secretion the affect can ISGylation situations, these “in that shows research The new cancer. and aging, oxygen, of lack a as such stimuli other by activated be also can it that show studies some although signal, antiviral an as mainly viewed past the in was ISGylation, called signal, The cells. neighboring into oras uh as such journals science leading in months past the over groups research These are some of the scientific highlights published by CNIC has characterized a cell signal that impedes inter impedes that signal cell a characterized has Madrid Na ence tu

re pub , , Cell Developmental Co mm un l , Medicine Experimental of Journal ish , , Circulation ica t i ons CNIC CNIC hi poaain n entry and propagation their facilitate to horses” “Trojan as exosomes use can viruses certain however, munication; com­ intercellular of means a as exosomes secrete Cells exosomes. called novesicles na­ of secretion that the impedes signal a characterizes ay Te td, published in study, The rapy. immunothe and design, ne vacci ­ therapy, gene as such strategies biomedical in to play role central a have could and communication cellular , , Medicine ature N , Communications ature N , , Communications ature N Prof. FranciscoProf. science IN IN

Sánchez- ature ature N

and ­ ­

uce n te omto o te odcin system. in conduction published the study, of The formation the and of muscle types different between cardiomyocytes to regulate boundary the maturation of metabolicthe contractile this establishes HIF1 which through mechanisms molecular territories metabolic embryonicthe discretewithinmyocardium; uncoversstudy thethe identified team CNIC The a transitory adaptation guarantee to the lack of oxygen. that genes of multitude mediate a of which activation the HIFs, or factors, transcription inducible oxygen. The key elements of this response are the hypoxia and nutrients of supplytissue reestablishthe to response adaptive complex a triggers oxygen, of levels the in drop ventricles.Hypoxia,a heart the formationcorrectof the in demonstrated the fundamental role of the hypoxiaby responseled CNIC the at Scientists in heartformation Hypoxia signalingplays aphysiological role to improve heartfunctionincardiovascular disease. “new open HIF signaling or modulate directly adjust the metabolic state in order also to intervention” and therapeutic function for opportunities and maturation its to myocardiumthe of status metabolic the linking processes molecular the on knowledge advance findings study The settings. disease of outsidehypoxia importanceof establishingthe essential an physiologicalprocess, in the formation pathwayof the heart chambers, hypoxia the of importance the D Matura Cardiac for Essential Switch Metabolic bryonic doi:10.1016/j.devcel.2016.11.012 (2016). S. Martín-Puig, ... L., Flores, L., J. Izquierdo-García, J., M. Menéndez , Cell Developmental tion. evel o pme Myocardial VHL Myocardial Montes, I., Escobar, B., Palacios, B., Gómez, B., Palacios, B., Escobar, I., -Montes, nt al C ell ­ Em an Controls Signaling HIF - eeomna Cell Developmental 39(6),724-739. Dr. S ilvia Martín-Puig ilvia , describes have - n h fibrilin the in diseases, defects aortic by caused disease in a syndrome, Marfan wall including aortic the of deterioration the arrest not do they because use limited of are treatments these However, wall. vessel the and on pressure reducing rupture, at arterial aimed therefore are of treatments pharmacological risk current the vessel The increases allow. dilatation conditions when repair surgical and requires management, therefore patient close diagnosis, accurate and early treatment Effective complications. fatal often and catastrophic, sudden, to prone condition dangerous extremely an is it however, symptoms; no or minimal provokes that condition indolent an an is aneurysm periods, long For wall. vessel blood pathological the a in from weakness resulting enlargement artery, an abnormal of or portion a swelling of a is aneurysm An scientist CNIC and Sols Alberto Biomédicas Investigaciones de Instituto CSIC the by codirected was study The aneurysm. aortic thoracic of treatment the in inhibitors and other types of aneurysm. The findings, published in in published findings, syndrome The aneurysm. Marfan of types of other and oxide model mouse a nitric in disease aortic protein—inducible reverse to a able is wall arterial the Nos2—in or of synthase inhibition The and similardiseases aortic aneurysm inmodelsofMarfan syndrome Inhibition ofaspecificprotein prevents andreverses N new pharmacological targets for slowing the natural natural the discover slowing diseases. these of progression for to targets and pharmacological degeneration new wall mechanisms the segment. aortic identify wall to underlying need artery a specific therefore is a There to confined progressive not is and which condition, underlying cure the not stem does or surgery Moreover, surgery. of that than is greater deemed is rupture of risk the intervention when only indicated dangerous this but surgery, is available Na tr Medicine ature tu re M edici - 1 gene. The only truly effective therapy therapy effective truly only The gene. 1 n , e suggest a major potential for NOS2 NOS2 for potential major a suggest Dr. Juan Miguel Redondo Miguel Juan Dr. Dr. Miguel Campanero Miguel Dr. . of of

INSIDE SCIENCE PULSE 27 INSIDE SCIENCE PULSE 28 cell lymphomaandprovide thebasisfor humantrials. B of treatment the for therapy analog miRNA first the of cell large development the diffuse to lead could findings and These lymphoma. lymphoma Birkitt of growth miR the synthetic of potential therapeutic the establishes Blood, in published study, The lymphomas. cell B of growth the blocking lymphocytes, B microRNA miR the discoveredthat team CNIC The lymphoma. aggressive have scientists very of types 2 for target therapeutic possible CNIC a identified year. every people 000 200 than with lymphoma every year, and B cell lymphomas kill more diagnosed are worldwide people 000 400 estimated An A newtreatment targetfor aggressive lymphomas syndrome model. Marfan mouse the deterioration, in and Adamts1 layer lacking mice in medial both aortic and dilatation aortic reverses effectively and rapidly production oxide nitric of further, also demonstrating that pharmacological inhibition goes study the But syndrome. Marfan of model Nos2 mouse in a and of mice these in inactivation disease aortic genetic prevents expression the Marfan that to and similar syndrome disease a develop Adamts1 lacking mice that demonstrates study The NOS2. synthase oxide nitric the and ADAMTS1metalloproteinase the aneurysm: of prevention and treatment potential the 2 for targets identified therapeutic study this on team research The B doi:10.1182/blood-201608 -731166 oxide mediates aortic disease in mice deficient in the the in deficient mice in disease aortic mediates oxide doi:10.1038/nm.4266 Méndez Oller,J., ... Ramiro, A. R. (2017). R. A. Ramiro, ... S., Roa, A., J. Olmo, del López M., S. Mur,F., Á. Prado, Bartolomé center reaction and blocks tumor growth in preclinical preclinical in growth tumor blocks and reaction center metalloprotease Adamts1 and in a mouse model of of model mouse a in and Adamts1 metalloprotease . Blood lymphoma. Hodgkin - non of models . . Medicine ature N syndrome. Marfan nard, M., Canelas, L. I., ... Redondo, J. M. (2017). M. J. Redondo, ... I., L. Canelas, M., nard, l oo d zued, . D Ybns V G, Álvarez G., V. Yébenes, De N., -Izquierdo, -28 regulates the terminal differentiation of Barbero, N., Ruiz, E. J., Villahoz, S., Re S., Villahoz, J., E. Ruiz, N., -Barbero, miR 8 nlg fr inhibiting for analogs -28 28 regulates the germinal germinal the regulates 28 -

Nitric Nitric - ­ and simple drug. simple and of safe, cheap, this for amount applications new to route the opens smaller post a the in tissue damaged into translates reduced The cell. inflammation blood of type a neutrophils, of action inflammatory the inhibits directly attack heart a during metoprolol of administration rapid beneficial: so is drug why this explains that (IIS mechanism the identified FJD), has Institute Research Health Hospital University Díaz Jiménez Fundación the at cardiologist a and CNIC the at The team led by if early. attack administered that heart a drug during produced a damage the metoprolol, limit can of action of mechanism new n hc a ahtr s sd o re to used is catheter a which angioplasty, in coronary Spain. of use years, in extensive recent the year in in especially deal a great a people advanced 000 has Treatment 50 that than disease more serious a affects is infarction myocardial Acute after aheartattack A decades-old drugstopsthespread ofinjury patient care and health policy. In an article published published article an In in policy. health and care both of patient terms in area research important extremely an is attack heart a by caused damage irreversible the limit health major heart impaired seriously long their limits that function have survivors attack heart many Nevertheless, artery. coronary blocked the through Na . Communications ature N size. infarct doi:10.1038/NCOMMS14780 B. (2017). B. Ibáñez, ... GarcíaI., -Lunar,A., Pun-García, E., Bernardo, Gutiérrez, R., Gómez R., Villena-Gutiérrez, J., García-Prieto, tu N tr Communications ature re Co mm Neutrophil stunning by metoprolol reduces reduces metoprolol by stunning Neutrophil - system costs. The search for treatments to to treatments for search The costs. system Dr. Borja Ibáñez un ica t i ons - infarcted heart. The finding finding The heart. infarcted , - NC cetss eot a report scientists CNIC term health and generates generates and health term , , Clinical Research Director - establish blood flow flow blood establish

- Tech, M., Tech, - appears also to have an educational role. The role. educational an have to also appears CNIC A to prevent their accumulation from causing tissue damage. cells damaged or dead, old, degrade and ingest cells lized specia­ whereby mechanism biological a is Phagocytosis Cell “cannibalism” trains ourdefenses Experimental Medicine Experimental organs. One could, for example, promote the elimination of in individual organs, without altering events in neighboring phagocytosis modulate to possible be principle in should to molecular toolkit for eliminating unwanted cells. According the researchers found that each tissue has its Surprisingly,own specific marrow. bone and liver the to gut the from tissue, each in process phagocytic the in tasks important out carry that molecules the detail in identifies study The process. this in role important very a play macrophages that and state, healthy and clean a in tissues maintain to how in system immune the of trains cells act expired the ingesting that is study the of conclusion important An that eaters”. “big means name a macrophages, called cells by out carried is damaged cells. This digestive process, called phagocytosis, or dead, old, the eat cells specialized that be to out turns mechanisms commonest the of One cells. from expired debris these the eliminate organisms how in interested been long have Scientists place. their take can ones new the the blood, skin, and die other tissues every day so that intestine, the in cells of billions which in in bodies, than own our evident more no is This life. of continuation for the prerequisite a is death that nature of paradox a is It cells thatcarry itout. immune the macrophages, trains also but cells, useless eliminates only not phagocytosis that shows study The and Alonso-González Noelia by coordinated was and USA, the from groups and (CSIC), Council Research Scientific Superior Spanish the (CNIO), Center Research Cancer National Spanish the from teams Jou “hs icvr sget ta it that suggests discovery “This Alonso-González, r n al e suy a nw eotd ht phagocytosis that reported now has study -led o f Ex perime report is the fruit of a joint effort by nt al of the CNIC. the of Hidalgo Andrés M edici n e Journal of of Journal Medicine in tissue in doi:10.1084/jem.20161375 A. Hidalgo, A. (2017). (2017). A. Hidalgo, Nicolás A., Aleja, la de González M., riegos, - this protective function. protective out this carry they which through mechanism the that describes shows also but only atherosclerosis against not protect cells B team marginal research the B specific subtype, this of cell role the examine Kingdom). to study (United first this In University Cambridge and CNIC the against atherosclerosis. The findings were published in in published were findings The atherosclerosis. against Marginal B cells, a subtype of immune cell, appear to protect in theprotection againstatherosclerosis ‘Unexpected’ role ofanimmunecell subtype N Na ozlz N, unaa J A, García A., J. Quintana, N., González, doi:10.1038/nm.4315 Newland, S., ... Mallat, Z. (2017). H., Z. Mallat, Y.... S., Newland, B. Lam, L., Masters, Y., Lu, P., A. Sage, M., Nus, - high a to cells T helper follicular of response the control . Medicine ature N diet. cholesterol tr Medicine ature tu re - . . resident macrophages. macrophages. resident M edici n by a team including researchers from from researchers including team a by e Phagocytosis imprints heterogeneity heterogeneity imprints Phagocytosis benefit. lasn mcohgs o our to macrophages cleansing oriae h wr o these of work the coordinate n ie t a b psil to possible be may it time in n haty sget that suggests healthy, and the body maintains itself clean h suy i dsrbn how describing in study, the plcto le i te future, the in lies application lhuh n therapeutic any Although of beneficial cells in the lung.”the in cells beneficial of ihu rsig elimination risking without dangerous cells in the spleen the in cellsdangerous Journal of Experimental Experimental of Journal Marginal zone B cells cells B zone Marginal

- iv, . Maza S., Silva, - Ávila, J. A., ...... A., J. Ávila, ­

INSIDE SCIENCE PULSE 29 INSIDE SCIENCE PULSE 30 immune response. the regulate that mechanisms the of understanding our B of differentiation terminal the during changestranscriptional of orchestration the in CTCF forfunction essential anreveals study research.The not function correctly, a finding with implications for vaccine infection.Inthe absence ofCTCF, the immune system does B of ability the for required is CTCF that shows research The production.antibody in CTCF regulatortranscriptional the suy e by led study A in theimmuneresponse CNIC scientistsdiscover anessentialmechanism rg diitain FA. oee, suy published study a However, (FDA). Administration Drug and Food US the by leukemia” for therapy “innovative an as authorized recentlywere Plk1 enzyme the of Inhibitors linked tocardiovascular problems A newanti-cancer drug N Na Na doi:10.1038/ncomms16067 ­ pro transcriptional centre germinal the orchestrates Pérez Ligos, J. M., Galjart, N., and Ramiro, A. R. (2017). R. A. Ramiro, and N., Galjart, M., J. Ligos, ­ differentia cell plasma premature prevents and gram , Communications ature N tion. ature Communications ature tu tu - ypoye t crety rtc te oy against body the protect correctly to lymphocytes re re -García, A., Marina - Co M edici mm un r Amdn Ramiro Almudena Dr. n e ica t i ons demonstrates an essential role for Zárate, E., Álvarez - ypoye ad advances and lymphocytes 8,16067. n pbihd in published and -Prado, Á. F., CTCF CTCF doi:10.1038/nm.4364 ­ ho vascular for required is and cells muscle smooth mitotic Malumbres, M. (2017). M. Malumbres, Méndez J., Martínez P., Wachowicz, G., Cárcer, De . Medicine ature N meostasis. in Cardiovascular disease and cancer are the main causes of causes main the are cancer and Cardiovasculardisease an appropriate bloodpressure. processmaintainingfor essential an wall, artery the lining cells of contraction the for essential is Plk1 that show to to Plk1 inhibition than other adult tissues. The team went on These sensitive more are effects. arteries the that cardiovascular indicated results secondary and artery cause rupture did it defects, Plk1 growth cause low while not with did strainlevels that mouse found a team of treatment CNIC volasertib and Research CNIO the London the Salamanca, the Institute, and in Salamanca, (CIC) de Cáncer Universidad del Centro Investigación the at de scientists with Together volasertib. with treatment and deficiency Plk1 genetic decreased from resulting with activity, characterization mice in the defects cardiovascular in of participated Redondo by led Miguel group research CNIC the study, new the In clinical trials. the in bytumor of type this against effectiveness therapy” its to due FDA “innovative an as recognized recently was and leukemiamyeloid acute in resultspromising very shown has which volasertib, inhibitor Plk1 the is strategy breastincluding cancer. this in used drugs new the Among cancers, various against usefulness their demonstrated the cycle, havecells, proliferationtumor controlsthe of processthat each cell the in of regulators alterations years, recent these In specific patient. targeting the to drugs according appropriate proteins the selecting on and proteins and genes depends our of each of medicine function the knowing personalized toward Progress cardiovascular severe problems. and rupture vessel blood to also but hypertension to only not lead can inhibitors these of use prolonged that suggests CNIC the at researchers with collaboration in (CNIO) Center Research Cancer National tr Medicine ature N abr, . Ecbr B, . Rdno JM and J.M. Redondo, ... B., Escobar, N., -Barbero, future biomedical developments. on impact major a have of will processes both control the in Plk1 of involvement The morbidity and mortality in modern societies. y eerhr fo te Spanish the from researchers by Plk1 regulates contraction of post of contraction regulates Plk1

Martínez, S., Oller, S., -Martínez, Juan ­ ih urn imnteay taeis Tee results, in published These strategies. immunotherapy current with and the other resident in tissues—that can be reactivated blood the in circulating cell—one T memory of types two cancerrequirescooperationto betweenresponse immune optimal an of generation that show results The response. anti - stronger a mount to cooperate lymphocytes immune essential sub­ of types different how investigated have researchers CNIC cancer immunotherapy The key toimproved by the prestigious journal prestigious the by selected was and treatment, revolutionizing cancer—is fight to system immune the of Immunotherapy—theuse the site oforigin). from metastasis distant organs of to tumor prevention the of the (dissemination to strategies, relation in immunotherapy especially cancer current improve to after surgery toremove the primarytumor. above all, it is a fundamental tool for impeding metastasis tumors; primary of rejection the promote effectively can cells. Cancer immunotherapy is not simply a treatment that treatments, and reactivation of both requires DC1 dendritic immunotherapy current with circulating reactivated be can subtypes both of tissue generation and the requires response anti- optimal an that suggests study The metastasis.” can be triggered to prevent the development of tumors and memory immune how particular in and effectively, more little however,is known about lymphocytes; how cytotoxic T T cells can be generated these reactivating on based is and recognize eliminate tumor cells should are inhibited. Current that immunotherapy lymphocytes T cytotoxic the “Cancer escapes the control of the immune system because advance of 2013. According to study leader Na doi: 10.1038/ncomms16073 - anti Enhanced Martínez A., J. tana, Quin­ J., F.Cueto, E., Priego, S., Iborra, M., Enamorado, between resident and circulating memory CD8+ T cells. cells. T CD8+ memory circulating and resident between , Communications ature N ban, M., Melero, I., Hidalgo, A. and Sancho, D. (2017). D. Sancho, and A. Hidalgo, I., Melero, M., ban, tu re Co eiet cl mmr. oh eoy cells T memory Both memory. cell T -resident m , Communications ature N un tumor immunity requires the interplay interplay the requires immunity tumor ica t i ao S, Mejías S., -Cano, ons cience S 8,16073 epne el cle C8 T CD8+ called cells -response as the major scientific major the as have the potential the have ée, . Este E., -Pérez, tumor immune tumor David Sancho, tumor ­ s oe cuae hn D ehius o etmtn an individual’s total plaqueburden. estimating for techniques 2D than accurate more is ultrasound 3D by volume plaque of quantification Direct areas, severalvolume. plaque atherosclerotic of in quantification including promise clinical shown already has it phase, development the in still is ultrasound 3D Although plaques. transducer that acquires 3D images volumetric of the arteries and linear atherosclerotic partner a uses technology system The CNIC Philips. by made system new a ultrasound with examined were patients The over years. several patients monitors that study is cohort PESA prospective a Madrid. were in based participants employees All Santander Banco stroke. of history or no infarction and myocardial symptoms disease no with cipants middle 3860 included population study The bifurcation. femoral the and sinus carotid the on centered In branches, both in segments arterial cm 6 of examinations arteries. ultrasound femoral 3D performed and researchers the territory, carotid each the of regions atherosclerosis most prone the explored scientists CNIC The than inother vascular territories,andincreases withage. arteries femoral the in higher is millimeters), cubic 25.7 versus (63.4 women in as men in high as twice is burden atherosclerosistotal years)the 45 age (mean participants ral Gene­ Director CNIC by directed study, the of results The and obesity). lesterol, blood pressure, diabetes, smoking status, exercise, cho­ (bloodfactors risk classical with togetherconsidered cardiovascularindividualwhen stratificationrisk,of the in that total atherosclerosis burden is a very useful parameter demonstrates report The participants. than aged middle more 4000 studies that Santander Banco and CNIC the Subclinical Atherosclerosis), a collaborative project between CNIC the ies. hs s h cnlso o a eot pbihd in published report,the a of conclusion the is This disease. for identifying individuals at risk of developing cardiovascularThree improves cardiovascular riskprediction 3D visualizationofcholesterol plaques Jou r so ta aog h study the among that show Fuster, Valentín Dr. Journal of the American College of Cardiology of College American the of Journal n - dimensionalcentralultrasoundtoolbecomea could al - o atne PS suy Porsin f Early of (Progression study PESA Santander f t he A merica n Co n lle g e o f C ardi gd parti­ -aged o l , og from y -

INSIDE SCIENCE PULSE 31 INSIDE SCIENCE PULSE 32 scientists in in scientists CNIC by published study A gene function New methods for analyzing each individual.” each in arteries the affect factors risk how about direct information gives atherosclerosis of extent and presence The atherosclerotic accurately. more risk individual predict to able be visualize will we body, the in directly size and number their to quantify and plaques ability the with Now, accurate. very not are factors events risk these on based cardiovascular severe predictions individualized however, of stroke); or (infarction risk of prediction population broad the a allow hy­ etc.) cholesterol, smoking, (blood pertension, factors risk “conventional that commented hospital university Díaz Jiménez Fundación Borja Ibáñez methods for studying gene function will allow researchersallow will function gene forstudying methods leader study to According of blocks building cells. our functional the to proteins, needed information synthesize the encode Genes disease. and development during of genes interaction and function the spatio high a allow will technology new The zebrafish. and mice as such models in mosaics genetic multispectral vertebrate analyze induce and to researcher any C ell Life: The PESA Study. Study. PESA The Life: - Mid in sound doi:10.1016/j.jacc.2017.05.033 (2017). Ruiz, J. M., Peñalvo, J. L., Gómez López , Cardiology of College rican -Melgar,FernándezB., ­ Ultra 3D by Burden Atherosclerosis Subclinical , CNIC Research Director , and CNIC Director Research at a cardiologist Cell will allow allow will - temporal resolution definition of of definition resolution temporal te improved the Benedito, Rui 70(3),301-313. -Friera,Oliva,L., GarcíaB., - - Talavera, S., ... Fuster, V. - Ame the of Journal

r dsraie ad cuily d nt fiinl detect appropriatelyactivatednot are cells B result, a As threats. efficiently not do crucially, and, disorganized are showed that, in the absence of caveolin-1, B cell receptors authors the models, experimental Using of lymphocytes. membrane B plasma the in receptors of clustering of the regulator crucial a as caveolin-1 identified team The insufficient immunefunction. by caused autoimmunity of model unique a in regulator key a as caveolin-1 protein the identified have CNIC the and (Germany) Freiburg of University the at researchers concept, new this Workingwith substitution. or activation be would strategy appropriate a an be and counterproductive, would situation, inhibitors pharmacological this on In based strategy responses. immune weakened of result as occur also can the autoimmunity that clear become considered immune been of result has diseases. autoimmunity autoimmune causes Historically, and body the attacks inappropriately, it activated is system immune our when threats disease as multiple such from us protects system immune Our Clustering for health ein f fiin teaetc taeis o oiy or modify to correct geneticactivityindisease. strategies therapeutic efficient of design the for crucial is moreover, knowledge, hierarchies.” This and bodies our understand up gene interaction networks and make their regulatory that types cell multiple the in operates genome the how about knowledge “increase to Na , Cell Analysis. doi:10.1016/j.cell.2017.07.031 Multispectral and Combinatorial Mosaic Gene Mosaic Combinatorial and Multispectral dito, R. (2017). R. dito, Fernández Pontes tu re aca V., Casquero-García, L., Heredia, S., -Quero, I mm Chacón, M., Luo, W., Hermoso, A., ... Bene ... A., Hermoso, W., Luo, M., -Chacón, uno 170(4),800-814e818. asn mcoe ad acr However, cancer. and microbes -causing Dual ifgMosaic: A Versatile Method for for Method Versatile A ifgMosaic: Dual - l ytm yeatvt. eety t has it Recently hyperactivity. system og y Function Function - ­ coordinate their studies of cardiac muscle after an acute acute an after muscle cardiac of studies their coordinate to agreement collaboration a signed Hospital University CNIC eetr i te cl mmrn esrs h correct the ensures membrane activation ofthesecells. cell B the of in organization receptors the that time first the for demonstrate results These responses. immune deficient generate and by by directed 10 York, New in than Hospital Sinai more Mount at ago begun years research from arose project The by followed is infarction progressive repair ofthemyocardium. an that view established the journals leading the in articles independent 2 in published study, infarction an to differs heart significantly from what was human previously thought. The the of response the that demonstrated have Hospitals University Salamanca and Scientists at the CNIC and the Fundación Jiménez Díaz (FJD) in theinfarcted heartcould leadtochangesintherapy Dogma overturned: newstudiesintoinflammation C irc doi:10.1038/ni.3813 dependent nanoscale organization of the the of organization nanoscale dependent - 1 - Caveolin (2017). Á. J., M. Pozo, Del G. ... K., Fiala, Raute, T., Osteso-Ibáñez, M., A. Schaffer, K., Klasener, S., Minguet, . Immunology ature N tolerance. cell B regulates BCR Valentín Fuster Valentín u - led studies. Two years ago, the CNIC and the FJD FJD the and CNIC the ago, years Two studies. led la t Circulation i on / CIRC / on , who is an author on both of the new new the of both on author an is who , and U LA T , Research Circulation I ON RE S EARCH overturns

so that the new algorithms can be tested in a clinical clinical a in tested be environment. can algorithms new the that so hospitals, collaborating to CNIC the the from transferring findings for initial imaging essential is cardiac input his the these and projects, leads of CNIC, development the at technological embedded researcher Philips Philips Iberia. Physicist Physicist Iberia. Philips partner technology and CNIC the between collaboration to the scientific thanks was possible project research This infarction.” the during supply blood the from off shut was that region entire the affects and prominent is inflammation/edema of wave second the when 7, and 4 days postinfarction between is been scans these for time optimal The have the that show period. findings new postinfarction studies the in day imaging any on conducted cardiac and considered important, not was question this now, Until reduce injury. to this interventions of effectiveness and the injury monitor irreversible to quantify to trials clinical in scans used MRI for timing best the about think to us “forces heart human the in of response discovery inflammatory bimodal the the estimation, his FJD In at Hospital. cardiologist University a of and CNIC Director the Ibáñez, at Dr. Research Clinical by coordinated was study The microcirculation.” the of real obstruction and hemorrhage, in expansion, volume infarction tissue an inflammation, including after time, occurring events visualize noninvasively to ability extraordinary an provides “MRI and author study of reperfusion words the In after heart. the of recovery hours rapid more much a in first result the during muscle cardiac the of composition the studies, change can infarction an animal and human during the that team allowing treatments to demonstrate in imaging comparable most research model translational for directly equipment includes at CNIC the unique infrastructure experimental The humans. the to pigs, similar in infarction of investigation their extended also have team the patients, re the after soon so MRI by patients attack heart study to world the in first the is study The infarction. myocardial Circulation tions for Assessing Myocardial Area at Risk and Salvage. Salvage. and Risk at Area Myocardial Assessing for tions of the Human Heart to Myocardial Infarction: Implica Infarction: Myocardial to Heart Human the of doi:10.1161/CIRCRESAHA.117.310901 zález, J., Agüero, J., López Agüero,J., J., zález, Fernández doi:10.1161/CIRCULATIONAHA.116.025582 Fernández S., ... Ibáñez, B. (2017). B. Ibáñez, ... S., , Research lation Protective Interventions on the Temporal Dynamics of of Dynamics Temporal the on Interventions Protective Tissue Composition After Myocardial Infarction. Infarction. Myocardial After Composition Tissue C., ... Ibáñez, B. (2017). (2017). B. Ibáñez, ... C., Sánchez A., cía, - establishment of blood flow. In addition to studies in in studies to addition In flow. blood of establishment - - . . Jiménez, R., Galán - R., Jiménez, Jiménez, R., Barreiro R., Jiménez, ■ - 121(4),439-450. González, J., Agüero, J., Galán J., Agüero, J., González, Dr. Rodrigo Fernández-Jiménez Rodrigo Dr. Effect of Ischemia Duration and and Duration Ischemia of Effect Dynamic Edematous Response Response Edematous Dynamic Martín, G. J., Gómez J., G. -Martín, Javier Javier Arriola, C., Sánchez C., Arriola, - Pérez, M., Martín M., Pérez, S ánchez- G onzález - Talavera, - Arriola, Arriola, - Circu -Gon­ - Gar a , ­ ­

,

INSIDE SCIENCE PULSE 33 INSIDE SCIENCE PULSE 34 multiple clinical data obtained in the participating cohorts:participating the obtainedin clinicaldata multiple the of richness the is project the of advantage main The same process.” the of spectra different are both if even both or entities between these nexus real a is really there if decipher us help will collaboration this but data, aggregated on based hypothesis were they now until Up disease. and Alzheimer’s impairment cognitive of development of risk the to related is disease cardiovascular of development the of risk the that idea the with speculating years spent have CNIC PESA the of researcher principal and CNIC the of Director General the part, his atherosclerosis”. For and Alzheimer between relationship the understand and investigate to Maragall opportunity unique a Pasqual us gives CNIC the and BBRC the the by of Director Foundation, the to According initiative worldwide inthissense. add up to more than 6,000 healthy individuals, the largest image and neuroimaging in their respective cohorts, which cognitive The image, vascular disease. of studies includes Alzheimer’s agreement and disease between atherosclerosis relationship the investigate collaborative to order a in start project to (BBRC), Center Research Brain Barcelonabeta the Foundation, Maragall Pasqual the of center research the and CNIC the led has association This share anunderlyingprocess. diseases both whether unknown remains it Nonetheless, disease. Alzheimer’s in involved protein main the also is the which brain, increase the in protein amyloid the depositing cumulatively of risk factors risk cardiovascular obesity, that shown been has it addition, like In lifestyle. sedentary a factors hyper risk hypercholesterolemia, hypertension, share Alzheimer atherosclerosis Both place. take and can stroke or attack a heart formation before years 20 the begins also arteries that the in known plaques of is with it occurs since same atherosclerosis, the And appear. problems memory characteristic the before years 20 to up produced start being can brain the in alterations Alzheimer, In of symptoms. case first the the of appearance the before much starts which progression, slow and long a presenting by characterized are atherosclerosis and disease Alzheimer’s Mu of T All wo l t - atne study, Santander iple

atherosc C

li of join , “the experience accumulated experience “the Camí , Jordi Dr. n ical

iance the Da

t afrs “we affirms, Fuster, Valentín Dr. together a l argest l lcma and ­glycemia erosis

to

for research

- work ontv tss n nw eriaig ehius in techniques neuroimaging new perform and will tests subgroup factor a cognitive risk and genetic disease, main Alzheimer’s the for is which determined, be now will gene APOE participants’ the agreement, this to the Thanks iliofemoralterritories. and coronary carotid, aortic, in disease atherosclerotic of presence the techniques detect to imaging cardiovascular non -invasive latest the using years 3 every evaluated PESA are the Study, Santander of participants the hand, other the On Alzheimer’s disease. developing of risk the with along evolution pre the in are they if detect to order in scans, CAT and ultrasounds get also will participants the on, now From development. factors and biological indicators that could contribute to its risk the identify to and disease the of history natural the financed by “La Caixa” Social Workinfrastructure, project, this is to of understand objective The 2012. since years, 3 genetic, every others, as cognitive, well as take tests, clinical and cohort, neuroimaging that Alfa volunteers the The in 55. and participate 40 of ages the between participants 4,184 with CNIC, of cohort Atherosclerosis) the PESA and 75, and 45 of ages the between participants 2,743 the Alfa (Alzheimer and Families) Study cohort of BBRC has

and

on

-CNIC phase of atherosclerosis and to evaluate their evaluate to and atherosclerosis of -phase science

cohorts

- Alz Santander (Progression of Early Subclinical

the

heimer prevention

in S pain -CNIC ’ s : -

adooy oit (E) a ld o h ceto o a of creation the to led has Spanish (SEC) the and Society CNIC Cardiology the between collaboration The h vsua ad eerl hne ta ae rdcd in atherosclerosis andAlzheimer’s disease. produced are that changes cerebral and between allow vascular relationship the the will of knowledge institutions of advance both the between experience and personnel, results, ideas, material, of exchange This CNIC. and BBRC from team multidisciplinary a will by analyzed cohorts be of both in levels obtained varying data with The atherosclerosis. individuals in changes brain or produced is deterioration cognitive if investigate to order C O LLAB n cud nld 2% f h tm ddctd o the to dedicated the time train to aims the program This program. CARDIOYOUTH of 25% include could and optional is year third The group. research a in integrated CNIC, the at be will year second The field. this in leader of supervision direct the Under Medicine. Tropical and Hygiene of School London prestigious the at methodology and statistics in Masters a studying Kingdom United the in be will year first The a be will This two- specialty. cardiology the in focused are and basic which of all biomedicine, cardiovascular in of used research clinical techniques latest methodology, the in training and translational statistics in training of profile a create cardiologist to is program this of objective The CARDIO www.cnic.es distinct tion processes, three and can be done through the into CNIC website: divided programs, all of which have is already opened their applica­ Program Training This P C N r year training program with an additional third year. third additional an with program training year O og IC- RA Y OUTH SEC-CNIC T I ON eerhr f xelne hog a specific a through excellence of -researcher S ram EC-Y C N IC & IC

S f OUT EC Professor o r Do H H S Trai , world Pocock, tuart c to n r i s ng ng f t sinit. utemr, hy il lo eev a receive also theoretical will training about cardiovascular they research. Furthermore, scientists. its of one ofsupervision the laboratoriescenter’sunder the at techniques in biomedical research that are being researched the resident students can get to know first cardiovascular research at the CNIC laboratories. This way, cardiology MIR program, offering the them doctorsthe opportunity in to be professional in stagestouch with resident 20 first their trainduring will program third The RES@CNIC EC-CNIC even afterthey finishtheirtraining. Health CNIC, and SEC the National of support the with respective counting Centers their at their projects develop to research continue to order in links establish to doctors resident eight chosen The by the SEC and CNIC will scientist. also have the opportunity a of supervision the under laboratories, CNIC the at research of project a through training, MIR the of years last their in residents cardiology the of training the complete to is months) six The purpose of this program (which lasts between four to INVEMIR SEC-C NIC network formed by nationalhospitalsandtheCNIC. a in them integrate and researchers cardiologist future shape duringtheirtimeatourcenter.” take to began that projects concrete through CNIC link the to permanent a have that hospitals international and national different in cardiologists are there currently and results important achieved have programs similar past, the In participants. the of stage training the to according objectives different have programs training “these that, three training programs for young cardiologists, comments the supervises directly who Madrid, in Hospital University Díaz Jimenez Fundación the at cardiologist and Research Borja Ibáñez, Director of the CNIC’s Department of Clinical medical andscientific professionals.” of that and training postdoctoral to education secondary CNIC the program, training global center’s the of umbrella the under coordinated is in effort This individuals research. cardiovascular outstanding and talented most the train and identify to effort exceptional an made has center the medicine, and training are basic pillars of the CNIC. Since translational its creation, effective research, in excellence For research.” cardiovascular of centers leading world’s the of one with together plan ambitious an such out carry to able been have to pleased very are We research. of society’s quality of without There assistance country. quality our our no promotion is in services the to cardiology the and in “responds quality excellence SEC with the commitment of to president specialized according which doctors cardiology, for in training postgraduate of plan , General Director of the CNIC, “the CNIC, the of Director General FusterDr.Valentín, - YOUTH Training Program, which covers all levels from r Adé Íñiguez Andrés Dr. ■ - hand the latest ,

INSIDE SCIENCE PULSE 35 INSIDE SCIENCE PULSE 36 that the main source of knowledge is the academic world. academic the is knowledge of source main the that paradoxcompanies.The the responsibilityof the extent, is in knowledge is R & D, sector while the marketing of such knowledge is, public to a large the of function main The says them“, marketing and in obtained research results the the to value’ ‘giving about is it the end, In economy. surrounding the mobilizing and people hiring projects, in investing of continuation the for allows research in financing public invested Administration - resources Public the the that time, “understands of passage the With and international calls tofinance national projects. of charge in were they originally although ago, to designed years30 Spain researchin emergedbring resultstogether offices first The framework. European and national the in both companies, and researchers between activities D & R in cooperation facilitate and encourage to structures as 1988 of end the at originated TTO new.The public research centers.” The TTO concept is not something and universities the in generated D & R the of results the of commercialization and application the to contributing thus sectors, private and public the between knowledge of transfer the improve to and sectors socioeconomic the of needs technological the identifying of charge in TTOare “the this, For CNIC. the at office the of charge in Martín, explains system, the of agents the among relations boost to is mission services. their and system, science enterprise the and in intermediaries are applications TTOs The processes, products, new generate to advances technological these developing in a interest to their evaluate can center who users of the number greater by generated and is advances scientific CNIC of technological diffusion the the of ensuring for (TTO) responsible Office Transfer Technology The ta l TTO a hv a eooi ‘eun that ‘return’ economic an have can - ent capita of

and ei López. Noelia oelia López Noelia - technology l

the i z

e - resources

the

academic is theTTO. and use those results for the benefit of society. The answer centers academic the in done is that resources and talent in investment the capitalize can you how is question The • • • • • • • • Dut

Negotiate terms and conditions of licensing contracts. licensing of conditions and terms Negotiate tion ofspin-offs. Transfercrea­entrepreneurship:through technology of Technological Offers portfolio. Identify commercial license opportunities for the CNIC’s offer/ of demand platformsand attending throughthe partnering/brokerage CNIC, events. the of results and activitiesresearch the disseminationof andPromotion article databasesandpatents. scientific in technique the of status the for Searching property right, tostudythemarket. intellectual by protected be can it if financing), is there idea from a technical, economic viability point of view (if other intellectual property rights. The objective and is to study the patents through CNIC the of property tual intellec­ the of protection and management Financing, potential industrialinterest. the and technology the of maturity the of Assessment come totheTTO withideasthatcan betransferred. who themselves researchers the is it that so it make we CNIC the at training internal through transfer.Also to susceptible be could work of lines which identify to and technical units of the CNIC and their research areas she explains, it is important to know all the laboratories disease,”clarifies any diagnose and treat to used be and commercialized be to potential the have that CNIC the in ideas tifying iden­ about “It’s commercially. exploited be can technologies that innovative of evaluation and Detection ie s o s

f investment t he

OT RI . In the case of the CNIC, the of case the In López. Noelia or

centers

how

TO of

of the technique, “it does not have to be obvious for an expert inthemattertohave come upwiththisinvention.”for obvious be to have not does “it technique, the of done something like it protected has to be ‘new’ to be able to present a patent application the object that is market exclusivity, territorial depending on where have the application is to filed. But State the by granted title patent a The results.”is the to value gives patent a Having tool. negotiation good very “a an is application patent a that of advice legal field. the this in specialized firm international on counts and rights property intellectual on advice for agency patent prestigious a with The TTO of the CNIC, directed by • • technical units generate new animal models and research and models animal new generate units technical state and laboratories both and has infrastructures and equipment CNIC the example, For technical capacities. and scientific in potential great its exploit can way,CNIC this the In contractingservices. collaborationor scientific through is transfer knowledge of form Another research anddevelopment. their in invested been have years many they that fact the despite licensed, be to unable are ideas the of many that your license then product to a company can to market it. But we must not forget CNIC The ideas. these achieve to of the CNIC, since it is the center that provides the resources The R & D results obtained by the researchers are property W

ha ments (CDA). Agree­ Confidentiality and (MTA) agreements transfer follow and management Negotiation, follow chers and local, national and international industry, and, Promotion of collaboration agreements between resear­ t t be - n up of private R & D projects. efi ts ts d o e s s - and taking into account the status i t t - nobody in the world must have pr o vide Enrique Lara, works closely

f o r t p f material of -up explains Noelia he C -of N IC? - the -art • • R &Dprojects andmakes theCNIC acenter ofreference. unique address to us allows this All in-house. materials P a

t i i t avne n h peeto, igoi and diagnosis prevention, the in advance to is aim The (MRI). Resonance Magnetic to scans CAT through the equipment,hybrid to ultrasoundfrom spectrum,entire in most technology the imaging have cardiovascular to advanced CNIC the allows Philips, collaboration partner, The Resonance:agree Magnetic Ultrafast leader even worldwide. makes Ferrerit an example and of how CNICSpanish innovation the can be by a developed that been fact has Trinomia The attack. heart a after occurs that heart the of remodeling prevents that antihypertensive an plaque,atorvastatininhibitor,ACE an and Ramipril, and to controlcholesterol levelsstabilize statin toand atherosclerotic a acid, acetylsalicylic thrombi, of formation the prevent to drug antiplatelet an ingredients:active three includes Trinomia, of name the under marketed medication,Thepublic fruitof and incident cardiovascular require treatment a to reduce the risk of a overcome second incident. have who availablesince January 2015.indicatedis It forpatients been has which atorvastatin of milligrams 20 only of one,previous the thandosage higher a withoption an in Spain a 40 milligram dose of atorvastatin is available, as well as the national agencies. Since September 2017, received the approval having of the European to thanksMedicines America, Agency, and Europe in markets 55 commercializationapprovedforFerrer.company is in It CNIC researchers in collaboration with the pharmaceutical secondarycardiovasculardevelopedby prevention was forEurope approvedpolypillin first Polypill:TheFuster e nts et ewe te NC n is technological its and CNIC the between ­ment - privatecollaboration and

INSIDE SCIENCE PULSE 37 INSIDE SCIENCE PULSE 38 CNIC to have the most advanced cardiovascular imaging technology in the entire spectrum the technologicalpartner,allowsPhilips, its and CNIC betweencollaborationagreement The by CNICresearchers incollaboration withthepharmaceutical company Ferrer cardiovascularsecondarydevelopedpreventionfor Europeapproved was in polypill first The • •

agreement, the Philips the agreement, collaboration this to Thanks program. research signed the to according and made, are field this as in updateadvances will Philips that technology disease the to cardiovascular thanks of treatment effective more n l ptet. h cmay at t dtrie the determine to wants company The patients. way all same in the work not does and out come already has that drug a involves the It transfer practice. clinical to to results order in fibrillation atrial in mechanisms involved of patients, and models animal in both collaboration a agreement has with Correvio International also Sàrl for the CNICstudy, The Fibrillation: Atrial for marketing during2018. and tissues cells. It is modify expected that this technology will be wayavailable this in and transfer for used genetic be can that company vectors viral non-integrative Spanish of the generation new a with of development the for VIVEBiotech agreement license a New generation of vectors: In 2016 the CNIC formalized vr 0 iue. h nw Philips new The minutes. 30 over of examinationtimes with complicatedtesttechnically to technique a is it bestbut heart, the of anatomy the and function the see is MRI developed. been has a milestone in the field of cardiac imaging. minute. This joint technological 1 development than represents less to times scan shortened has patent joint - CNIC VF CNIC - 3DESSOS joint patent joint 3DESSOS - NC VF CNIC - 3DESSOS • •

myeloproliferative of diseases. treatment the for therapy New and hypertension, pulmonary of treatment the for receptors adrenergic 3 of treatment lymphoid neoplasms; Use of selective agonists the of Beta- for agent therapeutic liver P38 New of cancer; prophylaxis Aneurysm; and treatment Aortic the for Thoracic inhibitors of Diagnosis and Treatment diagnosis; vivo in for radiopharmaceuticals New are: development in patents other others, Among At themoment theresults are positive. complicated. very be can diagnosis differential the and acute since infarctionmyocardial a mimics sometimes myocarditis infarction, myocardial and myocarditis acute of in diagnosis differential tool the for essential practice samples an clinical be blood would which patient minutes, 30 in in biomarker the detect to able biosensor the a develop to to company patent joint capital venture CNIC the the of for license myocarditis. underway and development acute is negotiation of a diagnosis been Currently, the already has for that patented biomarker a validated and work, of years 10 than more After myocarditis: in Biomarker ehns o ato i odr o civ a better a achieve to order selection of patients. in action of mechanism ’s group has discovered has group Fernández’s Martín Pilar

■ KING FE KING THE KING AND QUEEN QUEEN AND KING THE THEIR ROYA THEIR MET WITH REPRESENTATIVES WITH MET THE PR THE L IPE AND QUEEN L QUEEN AND IPE OF THE COMPANIES THE OF O C N THAT UP MAKE IC F IC OUN DA ETI T I Z ON IA IA L CNIC Foundation. the of Trustees of Board the of President Carlos , de of and CNIC the of explanations Director General FusterDr.Valentín, the to thanks excellence, of center this at place taking are that investigations relevant most the about know to Center, got Majesties Their year. Health last of February III Carlos and of King the Majesties Director their and CNIC the of and Innovation, Vice Crespo, and F. Jesús Development of Research, Secretary and of CNIC State the of Trustees of Board the of Equality; and Services Social by Accompanied MAJESTIES VISIT THE CNIC THE VISIT Mnse o Health, of Minister Montserrat, Dolors rsdn o te or o Trustees of Board the of -president iie te NC in CNIC the visited Queen President Vela, Carmen Luis Pro

CNIC & SOCIETY PULSE 39 CNIC & SOCIETY PULSE 40 President ofthePro CNICFoundation. indicated Commission”, Executive and Trusteesof Board its through Center the of management the in participation its with hand, other the on and years, last these in budget total the economically,of the 20% than more providing hand, one to On center. significantly the decade, of contributed development this in has During private, Foundation management. “the and and public funding combines both that through Foundation articulated Spain a in center research elite first the became CNIC result, a As project. scientific ambitious cardiologist prestigious the of incorporation the included also agreement The center. the whereHealth, the theyof committedfinancing Ministry to with agreement an signed 2005 in that companies The euros inthisperiod. is financing whose million 100 of contribution a explained with 2020, until guaranteed center, He the of present. situation also current was the CNIC, the of Director of Excellence of “Centers the Severo Ochoa”. of At the meeting, one as renewal its by has CNIC 2006 demonstrated as worldwide, institution leading a since become that achieved have the Foundation through that institutions and 14 companies the of representatives the with met Majesties Their s ae p f gop of group a of up made is Foundation CNIC Pro o ed this lead to Fuster Valentín Dr. Valentín Fuster, General us e Carlos, de Luis r CNIC Pro Dr. AlmudenaRamiro andDr.Sancho. David Benedito, as well as the CNIC researchers f ioa onain wr i Sinii Rsac of Research Scientific CNIC in Award Foundation Girona of in Excellence Research Spain”. Also present were the “Cardiovascularthree winners of the Princess scientific called a debate attended Majesties, Their Finally, CNIC. the at conducted being are that projects these of some hand Dr.Fogand Jacob CNIC, the from leaders group research three to speak to able were and center the of laboratories the visited authorities the of rest the and Majesties Their private the work of centers like the CNIC, a “paradigmatic model of support to sector private the for is it important how and CNIC the of features significant the of one as medicine” cardiovascular field. He also mentioned the use of “applied allows the excellenceresearchersin of of quarry a of creation and the people young to closer research biomedical CNIC called plan, training global develop a to possible been has it formula, funding this to part, his On of Circle Health” withhealthy tipsandchallenges.” “The as such applications mobile launching or the Heart”,that the morewith society general “Womencampaignsas such for the under and of operation, supervision into employees put been impacted have families, favorably their have that Plans Health Comprehensive CNIC, Pro by sponsored are that in health of improvement citizens by promoting healthy habits. “In all the companies the to contributed also has the years, last these Furthermore,in training duringallstagesoftheresearch career. long a on planned be to research allows CNIC to gives Foundation the that Spanish the of life of people”. quality and health the interest: social great of issue an to commitment firm “a also but R&D, to commitment firm a means only not companies added Additionally, S o cial Dr. Borja Ibáñez, Borja Dr. -public collaboration”. Co nelnd o te tbe funding stable the how underlined Carlos De mmi ihihe ta thanks that highlighted Fuster Valentín Dr. . Pro CNIC has also approached also has CNIC Pro Fuster. Dr. t her Majesty the Majesty her me , in order to know first know to order in Dr.Lara, Enrique - , the contribution of the of contribution the Carlos, de Luis nt em ai ad emt ivsig in investing permits and basis term Dr. Guadalupe knows very well, very knows Queen - OE, hc brings which JOVEN, Pro CNIC Foundation CNIC Pro and Sabio r Aa Dopazo, Ana Dr. Dr. Pilar Martín, ■ Dr. Rui Dr. - the promotion, theresearch andhealthcare.” possible makeit that areas all strengthen to and priority a is health that ensure to means possible all by try must We country. this in strongly believe “I added: he speech, improvement.”its to something contribute To his conclude has always beentheresearch ofwhat ishealthinorder to motivation “his that and enthusiasm great with challenge part, his On that contribute toamore active andhealthy ageing.” strategies “prevention promoting continue to necessary it makes which ones, main the of one as demographic the Minister. Among these challenges, the Minister pointed out overcomeus keyhelping them”,havea rolein will the said Council Advisory Health the and numerous are future the of System Health National the in face we challenges “The National HealthSystem are indebt tohim.” our and community medical international the Both world. the of rest the also but Spain in only not science hepatic in leader as “Spain put to able was he as legacy, his to for gratitude his expressed also Minister The healthy life. a promote to is mission whose Health; of Ministry the of Observatory Study Obesity and Nutrition the of President reference in the world for its research excellence.a He is also is which CNIC, the of Director General and Research in Sinai Mount Medical Center of in New York, Institute Prince of Asturias CardiovascularPrize Winner the of Director extensive professional career, as he is, among other things, presentation, the During whole country.” the and system health national the Equality, and services and experience his all knowledge at the disposal of the Ministry of Health, Social putting Council, Advisory the of she highlighted “his generosity in accepting the presidency “we that citizens General must the be active protagonists to of our own the health.” convey In to addition, of CNIC the efforts of the Director to recognition special paid of Equality, Minister and the Services Social Council, Health, the of President as Fuster Dr. of presentation official the In year. this earlier death his Rodés, who was the President of the Advisory Council until the Health Advisory Board to replace the deceased of President new appointed been has Fuster ValentínDr. H V ea new a ihihe ta h fcs this faces he that highlighted Fuster Dr. l l th ent recapped his recapped Montserrat Dolors

president A oos Montserrat, Dolors ■ dvisory r Rodés Dr. Dr. Joan í n -

and healthcare” the promotion, theresearch that make itpossible - and tostrengthen allareas to ensure thathealthisapriority “We musttryby allpossiblemeans health system andthewholecountry” Social Services andEquality, thenational at thedisposalofMinistry ofHealth, putting allhisexperience andknowledge the presidency oftheAdvisory Council, Dr. Fuster’s generosity “inaccepting Dolors Montserrat highlighted F V alent í uster n F uster

B of : oard

the ,

CNIC & SOCIETY PULSE 41 CNIC & SOCIETY PULSE 42 will have inthefuture that many ofusorourrelatives to thehealthproblems a betterapproach and thatwillgive us we are alljointlyresponsible for as aninvestment ofwhich as ahighlyvaluable asset, health research Society shouldconsider short or exchanges doing by world the of centers best the with contact in get to researchers allow or equipment improve by citizens can be used to generate new research contracts, provided funds the since campaigns, through sponsorship promote to try institutions scientific Some it. do to how know not do and help to want who individuals often are to donate their money for research projects, although there is what people for common of not is it ‘charity’.country traditioncalled our In greater a is there where countries Anglo- the in is it although Spain, in common very not is benefactor anonymous this of action selfless The CNIC. the to assets his all will his in donating heir’,thus National III Center Carlosfor Cardiovascular Research (CNIC) ‘universalhis as the name to decided has health research and scientific to committed citizen anonymous An the scientific community, as well as a very close personal close very of a as well forefront as community, scientific the the at be to considers he whom scientists, generosity, also has a deep respect for the work of Spanish In this case, the benefactor is someone who apart from his R A A e s pec - term stays there. benefactor t t f o r universa R e s earch

Saxon names relatives will have in the future. better future. the in have will a relatives us our or give us of many that will problems health the to that approach and all are for we responsible highly which of a jointly investment as an as research asset, health valuable consider should research. of Society promotion the in they economically another, people or participate way more this and in and more science is to are committed news there country good our The in today. that recognized sufficiently not generosity of act an is society, improve and life of quality for the increase that support research to dedicated institutions with benefactor’s its individuals connect to way a Philanthropy, investigation. appreciates CNIC The special consideration. deserved has reason that for and health of improvement the to research of transfer of example clear a represents each complement other. Precisely, for disciplines this generous benefactor the both CNIC how understand thus and research through advances new with medicine equip to to able need the activity hospital the been of day to day the in observe having health, of world the to experience

the l l heir CNIC CNIC ■ his

have travelled around more than50 municipalities. that buses the on exams medical free received have who years, the campaign has benefited 78,000 Spanish women, and Policies Family of the Community of Madrid in little Social more than two of Minister Deputy the to According of women againstcardiovascular diseases”. good work of “boosting the promotion of health and power importance of prevention and the need to keep up with the Equality, and Services Social Health, of Minister the anniversary, second its On of cardiovascular diseaseinwomen. impact the reducing maintain to contributes which lifestyle healthy to need the and symptoms the of recognition to inform the population about the importance of the early “Women for the Heart”. The main objective of this Project is of Madrid,have beenpromoting theAwareness Campaign Community the Foundationand Heart Spanish the dation, the Foundation, Mapfre the 2014 Since diseases (11,08%). system respiratory and (27,86%) cancer above it places Spain. It represents 30% of total deaths, a percentage that Cardiovascular disease is still the leading cause of death in “W of

omen the , highlighted the highlighted Montserrat, Dolors A S wareness econd r CI Foun­ CNIC Pro

for

f h journalist the of Dr. Valentín the Fuster of Director (CNIC), Centre General ResearchCardiovascular National III the Carlos by up backed project, The a heart attack. to helping will women identify the warning signals and prevent year the throughout contribute whom selflessly in broadcasting messages and that are key initiative, this of N A the aranjo and the athletethe and nniversary C ■ n Rosa Ana , will count on the unconditional support H ampaign Ruth BeitiaRuth Q eart uintana , deluxeambassadors, te singer the , Mónica ”

CNIC & SOCIETY PULSE 43 CNIC & SOCIETY PULSE 44 N Foreigntheof Affairs Department AMED,of President, its Through Japan. in development and research through medicine improving to dedicated institution an is (AMED) The Japanese Agency for Research and Medical Development Development and Innovation,Developmentand DolorsMontserrat panied by the Minister of Health, Social Services Cardiovascularandaccom­ of(CNIC)ResearchCentre NationalEquality, Commission, TheHealth and Food Safety Commissioner of the European V oda isit for , and the First Secretary First the and , of

Mr. Makoto Mr. from R yei Andriukaitis Vytenis

the esearch ; the Secretary of State of Investigation,SecretaryStateof theof ; S

E uematsu the uropean Carmen VelaCarmen - Commissioner of Science of Commissioner H , the Managing Director Managing the , vstd h Cro III Carlos the visited ,

and ea T l he ; the Executivethe ; Mr.Masahiko th M

J

edica and apanese Food l D l Basic Research at the CNIC. Director of Clinical Research and CNIC,the ofManager the Institute,Health III Carlos the of Food Consumption, of Nutrition,Safetyand Agency Spanish the of Director Vicente Andrés CNIC, the Research Cardiovascular of (CNIC), Centeraccompanied by National III Carlos Spain, in Embassy Aoki JapaneseMasahiro Mr. the of – Technology and C eve Safety Borja Ibáñez Borja ommission l opment , Director of Basic Research of the CNIC. , the AMED visited the facilities of the of facilities the visited AMED the , T eresa Robledoeresa , Director of Clinical Research, and Research, Clinical of Director , Alberto C A Alberto ■ ommissioner S gency Vicente Andrés

anz Jesús FernandezCrespoJesús at S anz , Managing Director of ; the GeneralDirectorthe ;

, and , the Borja IbáñezBorja , Director of CNIC ■ ; ,

odce i 1 cutis te rbblt o female of a in probability PhD and master’s bachelor’s, the a completing students countries, 14 in them conducted preventing study a to According barriers field. this in participating with fully the from faced promote still and are inspire women to effort big participation of women and girls in science. Unfortunately, a made has community international the years, 15 last the In Agenda. the meet to Sustainable essential Development Goals, included in are the UN’s 2030 equality gender and Science F. Crespo, Director oftheCarlos IIIHealthInstitute. Director of the Women and Science Unit (UMYC); and State for Research, Development and Innovation; of presence the with counted who (CNIC), Center Research Cardiovascular National III the at International Women and Girls debated in Science Day wereat the Carlos that issues the of some are These to positive? families life, family and and professional personal, conciliate institutions of co -responsibility the or evaluation in biases gender systems, barriers, language of removal quota the Are Development? and Research in equality impede that stereotypes the of rid get to system educational informal and formal the in changed be must What researcher? a becoming in there are barriers What W , Secretary of Secretary Vela, Carmen omen I nternationa in Ana Puy, Jesús S at in Science Day. Science in Women and Girls as 11th February International proclaim to decided Assembly General UN the girls, and women of and empowerment and access girls, equality gender and equal achieve to women and moreover for full science achieve in to participation and able be to order In the probability for malestudents is37%,18%and6%. science ‘mentoring’ hasontheeducation oftheyoungest. way. different stages of the scientific career and the importance the along find may Furthermore, participants were able they to know first difficulties the vocation their despite up give to not researchers female future motivate to intend they which with career,research their this of stages different in CNIC the at researchersfemale with from initiative this in severaltestimonials with video a showed conference,and participated has CNIC The R e cience s earch

and related field is 18%, 8% and 2% respectively,2% while and 8% 18%, is field -related C

areer the G CNIC D ir ay l -hand the ■ s l l

CNIC & SOCIETY PULSE 45 CNIC & SOCIETY PULSE 46 Promega BiotechIbéricaS.L.gave ‘M in theMarch ‘Move for theCNIC’, to theCNIC’s trainingprograms an economic contribution For eachpersonenrolled ove M arch

for says health within the community and the working of environment,” type initiative is a this great idea because it throughintroduces the concept of health cardiovascular “Promoting CNIC’s training programs. Promega the to enrolled, contribution economic an gave person S.L. Ibérica Biotech each For modality. other healthy any or cycling jogging, walking, for opted families their and S.L. Ibérica Biotech Promega of and CNIC the of ‘enthusiasts‘ sports participants, the where track, km 10 a included and PardoEl at held wascardiovascular health This sports day to support scientific research and promote the interest ofresearch inyoung people. fostering at ‘Approach‘, aimed program the with to helping linked be will the participation of whose and activity workers, CNIC cardiovascular the promoting at aimed initiative CNIC’,responsible socially the for a ‘Move March the CNIC the with collaboration in organized, S.L. Ibérica Biotech Promega Therefore, example. by preach to than health cardiovascular our of care take to better Nothing and professional well personal workers’ the pursues end the in that event this in necessary partnercollaborative “a CNIC, the with done of workers with initiatives such as the one that is now being said that his company works to promote the healthy habits Jochems

for Dr.Valentín Fuster

, General Director of Promega Biotech Ibérica S. L, PromegaGeneralBiotechIbéricaS.Director of , the S - being”. , General, DirectorCNIC.the of cience ■ CNIC’ G ijs : “S oois r mesn it te xiig ol o science through experimentation. of world exciting the into immersing or robotics astronauts”,weigh to “chair learning a seeing kitchen, the in and science reality, bounce virtual magic”, that “scientific color, eggs change discovering like held, also were In addition, during the “Scientific Weekend”, other activities Pokémon’s reconstruct phylogenetic tree. to and made, explain are to proteins used how was which acids, amino gummy using Potter Harry of help the with code genetic the explaining of consisted CNIC by organized activities other Twothe of the striatedmuscle. sarcomere contracts, the the anatomical and functional how unit of see also could they Furthermore, makes. the heart that sound the and shape the discovered also They technology. sophisticated most the with laboratory a in done be only can that something microscope, the through the functioning of the heart. For example, they saw a heart first discover to able were CNIC who the of girls stand the and approached boys The technology. and science so about games all learn could Alcobendas and in fair this of workshops visitors the that activities, 200 than prepared them more of All CNIC. the including in weekend, participated this Spain over all from institutions 40 than Caixa”.“la WorkMore Social the of collaboration the with May, of 28th and 27th the on Alcobendas in (MUNCYT) Technology and Science of Museum National the at year for all audiences, was celebrated for the fourth consecutive The VIII edition of the “Scientific Weekend”, the science fair -hand everything they had ever wanted to know about cientific ■ T he CNIC P CNIC W eekend articipates

in ”

CNIC & SOCIETY PULSE 47 CNIC & SOCIETY PULSE 48 for healthy ageing, a healthy middle age, and a healthy healthy a and age, middle healthy a ageing, healthy for course, the During inaugurate theConvention center, CCCardona. to served also event The city. priority the of promotion economic a becomes and social for tool health a and Cardona of citizens the for issue where Cardona project in a held initiative, was course Integral‘ ‘Cardona the launched this that city the (Barcelona), time first the For Europe. and America Latin from them of many countries, 15 over from also professionals specialties of presence the other with counted also it year, or This attended. medicine internal other in 300 although experts than cardiologists, more them of future” most to the attendees, tried for he teach and where “motivate Laboratories, Ferrer (UIMP), by Pelayo sponsored by Menéndez University organized Bases Health”, International Population and the & Disease Cardiovascular Clinical of “Molecular, course the Hospital, Sinai Mount of Institute Cardiovascular the and CNIC the of director The “M of o C l ecu ardiovascu r Fuster Dr. l r Vlní Fuster Valentín Dr. ar analyzed the foundations foundations the analyzed M , Cl , D r aster inica . V . , taught taught , l a ar l ent l & P & l D strategies to improve cardiovascular health among the the population,” general stated. he among health cardiovascular improve to strategies current of foundation the be should routine, diet healthy not a and activity include physical regular obesity, avoiding which smoking, habits, lifestyle healthy CNIC. the “Promoting of take Director to General late the too said yourself”, of never care is it insist message: must important you an general And on a lifestyles. and and attitude responsibility of change individual of matter health a our is of care “Taking adolescence. and childhood to take care ofyourself” message: itisnever toolate And you mustinsistonanimportant of attitudeandlifestyles. and ageneralchange is amatterofindividualresponsibility “Taking care ofourhealth V isease alent í n opu F í n C F uster uster l

and ourse ation : ■

H teaches ea Bases l th ”

the metabolismimmunecells.“Weinterestedaretheof modify signals danger or microbes of detection the howresearcher, showthat studiespioneer arethere functional of manipulation responsesimmunecells.inexplained AsCNIC theby the for generate targets can new that research of field emerging an Dr. of “Science excellence”. 2020 Horizon Program, Innovation and ResearchEU’s the of part are and euros million 605 is (EU) Union European the of Council Research European the by granted subsidies of amount total innate amount of 1,995,000 euros over the next 5 to years. The adaptations subsets”,cell dendritic an receivein will sensing which metabolic mitochondrial of best 314 David the to Grants researchers Consolidator in Europe. Among the them is its a CNIC researcher, announced of (ERC) winners Council Research European The The to t to AND SCHO AND S Eu he ancho , for his project “Functional characterization“Functional project his for Sancho,

r re o pea ’s project focuses on immunometabolism, s earch n n U n o i on g on f D r . David . ra nts 2 nts

Sa milli n ch on on o o a t t t e u he r os os C N IC Dr. L University of Oviedo. of University once again, by by again, over, research once presided been has award epidemiological this of jury and The profiles. clinical basic, of included Biomedical which field the submitted were of applications the 58 of total edition a Award, in twelfth the researchers In young biomedicine. of trajectory the acknowledge to aims and euros 50,000 with endowed is prize The pathology. this of the treatment to and prevention technology through and knowledge diseases basic of cardiovascular transfer the against fight the to contribution innovative his for award 2017 the of winner the as (CNIC), Research Cardiovascular of Centre National Cabeza acknowledged has Research Biomedical for Award Foundation Sabadell Banco XII the of jury The t f D he o r r . Bo .

B AWARDS AWARDS X ARSHIPS II B II i o rja , Director of Clinical Research at the Carlos III III Carlos the at Research Clinical of Director , medical a I n bá c o o ñ Sabadell Dr. Carlos López López Carlos Dr. e z z R awarded e s earch Foun

da O t tín i on A on , professor at the the at professor , Dr. Borja Ibáñez Ibáñez Dr.Borja ward

CNIC & SOCIETY PULSE 49 CNIC & SOCIETY PULSE 50 n Erh cecs Boeiie Ifrain and Management, Business and Information areas Economics Architecture; and Engineering Biomedicine; Other Technologies, Sciences; Communication Environmental Earth Biology, and Sciences; Basic — Cultural categories and nine its of out Researchers seven in awarded been now have Creators for Scholarships Leonardo cancer”.2017 liver The for target therapeutic possible P38gamma as of “Inhibition project her for research basic and of area the Researchers in Foundation BBVA to the of Creators Scholarships Cultural Leonardo 50 the of Researcher o te eeto o dne sgas rm irbs or microbes from signals danger of detection the how characterize 1) are: project Sancho’s Dr. of objectives The pattern of cytokine production.” its andmacrophage the of capacitybactericidal the alters the modification this in that electrons and chain transport of mitochondrial flow the changes macrophages by Our cells. previousrecognitionshownthethatworkhas microbes of dendritic by damage tissue or microbes from metabolictheconsequences in detectingofdangersignals G to R to u adal e s earcher u pe Guadalupe

Sabi s s o o a receive n d Cu o te NC rcie one received CNIC, the of Sabio, l tu s L s ral e on C ard rea to o o Sch r s o s o f lar t he s hip BBVA Foun BBVA

Honor”, among which are also are which Honor”,among Dr. recognition, this With areas. all in women of presence the boosting at aimed initiative an 2017, in Spain in Leaders Women 100 Top the among chosen women 100 the of amn Alborch, Carmen Almudena Literary and Humanities; Theatre. Sciences; and Creation social and Legal author. Martínez Alonso,amongother important figures. Otero, preclinical approach. a as areessential which disease, of models animal in cells the manipulation of mitochondrial metabolism in dendritic cells; 4) evaluate possible therapeutic approaches through dendritic human and mouse of function and metabolism impact of the manipulation of mitochondrial biology on the the address 3) metabolism; mitochondrial the and signals the dissect 2) human; and molecular mechanisms that connect the detection mouse of these metabolism in cells mitochondrial dendritic in modulates damage tissue pulmonary vascular response to chronic hypoxia” hypoxia” chronic the to regulates response ZIP12 ( vascular transporter the zinc pulmonary of “The publication the article for European of Societies Federation the Pharmacological by year the last to added received is one award This Granada. of University the with the other award winner winner award other the with career. divided be to is which scientific 1200€, members of Pharmacology, best prize a has the award its This with to of age of grants years 35 Society society under this Spanish that the recognition of Award Eduardo o R Young E N d f da ature t u becomes part of the very select group “Top of “Top group select very the of part becomes Sabio ard he t i on agrt Álvarez , Margarita

Spa , 05 524:356 2015; o o e O s Oliver liver Grandes, n earch i s has been granted the Young Researcher Researcher Young the granted been has h

S g amn Iglesias, Carmen A o ra cie Amaya Arzuaga, Amaya ward Dr. nt t y ed o - Guadalupe

360), where he is the main main the is he where 360), or Alonso José María f

P Her Majesty Letizia Majesty Her harmac iul Romero Miguel rn Milleiro, Irene Amaya Valdemoro , Amaya i as, one also, is Sabio, o l og y , from from , Marta Ortiz, Julia Fuster “La Caixa”, accompanied by doctors and Health. assets: Fainé Isidro valued highly most and the of diseases one against preserve fighting lives their dedicate who scientists of contribution the and people of welfare the in research of importance the recognize to wants Caixa” “La Foundation Bank the of campaign ‘Imprescindibles’ The Clotet The B Jaume Jaume and and a , , n Maite Mendioroz Maite k Foun Pedro Alonso Pedro G , president of the Bank Foundation “La Caixa”, “La Foundation Bank the of president , iró , General Director of the Bank Foundation Foundation Bank the of Director General , da t i on “ on , , , presented the new advertising advertising new the presented , Eduard Eduard la C ai x G a María María Blasco ratacós ” pay s t s , , Bonaventura Bonaventura rib , , ut Valentín Valentín e to to bi o medical Science and Education.” and Science health: cardiovascular promoting to keys two are “there Fuster Dr. are them Among research. their of points important most the explains and leaders scientific the gathers of testimonies campaign the The world. the of rest the greatest on the impact have that diseases the fighting of aim the with issues, health in humanity of challenges great the to respond to work that excellence of research of field the in year to wants give this voice to that leaders the campaign

re s earcher , General Director of the CNIC, who notes that that notes who CNIC, the of Director General , s ■

CNIC & SOCIETY PULSE 51 TRAIN2GAIN WHAT’S ON INSIDE SCIENCE CNIC & SOCIETY PULSE otoño’17